1 PURPOSE

1.1 This policy establishes the definitions followed by the human research protection program. This is a non-exhaustive list and regulatory agencies should be referenced for complete definitions where applicable.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 Adverse Event (AE): For Veterans Administration (VA) human subjects research any untoward physical or psychological occurrence in a human subject participating in research, whether or not considered related to the subject’s participation in research.

3.1.1 Adverse events are untoward diagnostic or therapeutic incidents, iatrogenic injuries, or other occurrences of harm or potential harm directly associated with care or services delivered by VA providers.

3.2 Allegation of Non-Compliance: An unproved assertion of Non-Compliance.

3.3 Assurance of Compliance (Human Subjects) or Federalwide Assurance: An assurance is a written commitment to protect human research subjects and comply with the requirements of the Common Rule.

3.4 Authorization Agreement: Also called a Reliance Agreement, is the agreement that documents respective authorities, roles, responsibilities, and communication between an institution/organization providing the ethical review and a participating institution relying on the ethical review.

3.5 Certificate of Confidentiality: A Certificate of Confidentiality is a document issued by a component of HHS pursuant to The Public Health Service Act Section 301(d), 42 U.S.C. 241(d) amended by Section 2012 of the 21st Century Cures Act, Public Law 114-255, to protect the privacy of individuals who are subjects of certain specified research activities by authorizing investigators to withhold from all persons not connected with the conduct of such research the names or other identifying characteristics of such subjects. Persons so authorized to protect the privacy of such individuals may not disclose information in any Federal, State, or local civil, criminal, administrative, legislative, or other proceedings to identify such individuals.

3.6 Certification: The official notification by the institution to the supporting Federal department or agency component that a research project or activity involving human subjects has been reviewed and approved by an IRB in accordance with an approved assurance.

3.7 Clinical Trial: A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

3.8 Collaborative Study: A study in which two or more institutions coordinate, with each institution completing a portion of the research activities outlined in a specific protocol.

3.8.1 For Veterans Administration (VA) research, Collaborative (Study) Research involves human subjects research activities involving investigators from VA and at least one non-VA institution. Collaborative Research includes VA and non-VA institutions.

3.9 Conflicting Interest:

A financial interest Related to the Research is when the individual or the individual’s spouse, domestic partner, children, and dependents have any of the following interests in the sponsor, product or service being tested, or competitor of the sponsor held by the individual or the individual’s Immediate Family:

3.9.1 Ownership interest, stock options, or other ownership interest of any value exclusive of interests in publicly-traded, diversified mutual funds.
3.9.2 Compensation of any amount including, but not limited to honoraria, consultant fees, royalties, or other income, excluding compensation for costs directly related to conducting research.

3.9.3 Proprietary interest including, but not limited to, a patent, trademark, copyright or licensing agreement.

3.9.4 Board or executive relationship, regardless of compensation.

An individual involved in research review is automatically considered to have a conflicting interest when the individual or the individual's spouse, domestic partner, children, and dependents have any of the following interests in the sponsor, product or service being tested, or competitor of the sponsor held by the individual or the individual's Immediate Family:

3.9.5 Involvement in the design, conduct, or reporting of the research.

3.9.6 Ownership interest, stock options, or other ownership interest of any value exclusive of interests in publicly-traded, diversified mutual funds.

3.9.7 Compensation of any amount in the past year or of any amount expected in the next year, excluding compensation for costs directly related to conducting research.

3.9.8 Proprietary interest including, but not limited to, a patent, trademark, copyright or licensing agreement.

3.9.9 Board or executive relationship, regardless of compensation.

3.9.10 Reimbursed or sponsored travel by an entity other than a federal, state, or local government agency, higher education institution or affiliated research institute, academic teaching hospital, or medical center.

3.9.11 Any other reason for which the individual believes that he or she cannot be independent.

3.10 Continuing Non-Compliance: A pattern of Non-Compliance that suggests the likelihood that, without intervention, instances of Non-Compliance will recur, a repeated unwillingness to comply, or a persistent lack of knowledge of how to comply.

3.10.1 For Veterans Administration (VA) research Continuing Non-Compliance means repeated instances of noncompliance with applicable laws, regulations, policies, agreements, or determinations of a research review committee or the prolonged persistence of noncompliance occurring after its identification, awareness, or implementation of a corrective action intended to effectively resolve the noncompliance.

3.11 Designated Reviewer: The IRB chair or an Experienced IRB Member designated by the IRB chair to conduct Non-Committee Reviews.

3.12 Experienced IRB Member: An IRB member is considered experienced if the IRB chair considers the IRB member to have sufficient experience in and knowledge of conducting IRB reviews.

3.13 Expiration Date: The end date of the approval period.


3.15 Human Research: Any activity that either:

3.15.1 Is Research as Defined by DHHS and involves Human Subjects as Defined by DHHS; or

3.15.2 Is Research as Defined by FDA and involves Human Subjects as Defined by FDA.

3.16 Human Subject as Defined by DHHS: A living individual about whom an investigator (whether professional or student) conducting research (1) obtains information or biospecimens through Intervention or Interaction with the individual, and uses, studies, or analyzes the information or biospecimens; or (2) obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens. For the purpose of this definition:

1 The terms “Human Subject Research,” “Research Involving Human Subjects,” “Clinical Research,” “Clinical Investigation,” “Clinical Study” and similar phrases are considered to be synonyms for the term Human Research.
3.16.1 **Intervention:** Physical procedures by which information or biospecimens are gathered (for example, venipuncture) and manipulations of the subject or the subject’s environment that are performed for research purposes.

3.16.2 **Interaction:** Communication or interpersonal contact between investigator and subject.

3.16.3 **Private Information:** Information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and that the individual can reasonably expect will not be made public (for example, a medical record).

3.16.4 **Identifiable Private Information:** Private Information for which the identity of the subject is or may readily be ascertained by the investigator or associated with the information.

3.16.5 **Identifiable Biospecimen:** A biospecimen for which the identity of the subject is or may be readily ascertained by the investigator or associated with the biospecimen.

3.17 **Human Subject as Defined by FDA:** An individual who is or becomes a subject in research, either as a recipient of the test article or as a control. A subject may be either a healthy human or a patient. A human subject includes an individual on whose specimen a medical device is used.

3.18 **Immediate Family:** Spouse, domestic partner; and dependent children.

3.19 **Institutional Official/ Organizational Official (IO/OO):**

3.19.1 **Institutional Official (IO):** Term utilized by DHHS.

   3.19.1.1 The Institutional Official (IO) is the individual who is legally authorized to act for the institution and, on behalf of the institution, obligates the institution to the Terms of the Assurance. The IO is responsible for ensuring that the Human Research Protection Program (HRPP) functions effectively and that the institution provides the resources and support necessary to comply with all requirements applicable to research involving human subjects. The IO represents the institution named in the Federalwide Assurance (FWA)\(^2\). The IO is Associate Vice Provost for Research.

3.19.2 For Veteran’s Administration (VA) research, the Institutional Official (IO) is the individual legally authorized as Signatory Official to commit an institution to an FWA. The Signatory Official assures that human subjects’ research to which the FWA applies is conducted in accordance with the terms of the assurance (see VHA Handbook 1058.03). The Principal Deputy Under Secretary for Health or designee is the IO for VHA Central Office, and VA facility Directors are the IOs for local VA facilities.

3.19.3 **Organizational Official (OO):** Term utilized by AAHRPP.

   3.19.3.1 An identified, knowledgeable leader of the HRPP who is responsible for the program and has the authority to implement the program. This individual may rely on others for the interpretation of laws, regulations, codes, and guidance and the day-to-day operations of the HRPP, and should have a basic understanding of the relevant laws, codes, regulations and guidance that govern research involving human participants, the responsibilities of an organizational official, and the responsibilities of the IRB or EC and researchers and research staff in protecting research participants. This individual should be directly involved in the allocation of resources to the HRPP. In some circumstances, more than one individual serves in this capacity\(^3\).

---


SOP: Definitions

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>DATE</th>
<th>AUTHOR</th>
<th>APPROVED BY</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRP-001</td>
<td>12/10/2021</td>
<td>M. Williams</td>
<td>M. Meyer</td>
<td>4</td>
</tr>
</tbody>
</table>

3.20 **Institutional Profile:** A record of information an institution keeps about another collaborating institution/organization for one or more Collaborative Studies or Multi-Site Studies.

3.21 **Investigation:** A searching inquiry for facts; detailed or careful examination.

3.22 **Legally Authorized Representative (LAR):** An individual or judicial or other body authorized under applicable law to consent on behalf of a prospective subject to the subject’s participation in the procedures(s) involved in the research.

3.22.1 If there is no applicable law addressing this issue, then this individual is recognized by institutional policy as acceptable for providing consent in the non-research context on behalf of the prospective subject to the subject’s participation in the procedure(s) involved in the research.

3.22.2 See HRP-013 - SOP - LARs, Children, and Guardians for who may serve as a Legally Authorized Representative at this institution.

3.23 **Minimal Risk:** The probability and magnitude of harm or discomfort anticipated in the research that are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.\(^4\)

3.23.1 For research involving prisoners Minimal Risk is the probability and magnitude of physical or psychological harm that is normally encountered in the daily lives, or in the routine medical, dental, or psychological examination of healthy persons.

3.23.2 When following Department of Defense regulations, the definition of minimal risk based on the phrase “ordinarily encountered in daily life or during the performance of routine physical or physiological examination or tests” shall not be interpreted to include the inherent risks certain categories of human participants face in their everyday life. For example, the risks imposed in research involving human participants focused on a special population should not be evaluated against the inherent risks encountered in their work environment (e.g., emergency responder, pilot, soldier in a combat zone) or having a medical condition (e.g., frequent medical tests or constant pain).

3.24 **Multi-Site Study:** A study in which two or more institutions coordinate, with each institution completing all research activities outlined in a specific protocol.

3.25 **Non-Committee Review:** Any of the following:

3.25.1 Determination of whether an activity is Human Research.

3.25.2 Determination of whether Human Research is exempt from regulation.

3.25.3 Reviews of non-exempt research using the expedited procedure.

3.25.4 Determinations of which subjects can continue in expired research.

3.25.5 Concurrence of IRB Chair or designee for non-emergency individual patient/small group expanded access for an unapproved medical device (commonly known as Compassionate Use) or non-emergency individual patient expanded access IND with request for authorization to use alternative IRB review procedures.

3.26 **Non-Compliance:** Failure to follow the regulations, or the requirements or determinations of the IRB.

3.26.1 In the case of research funded or conducted by the Department of Defense (DOD), Non-Compliance includes failure of a person, group, or institution to act in accordance with Department of Defense (DOD) instruction 3216.02, its references, or applicable requirements.

---

\(^4\) The phrase “ordinarily encountered in daily life or during the performance of routine physical or physiological examinations or tests” should not be interpreted to include the inherent risks certain categories of subjects face in their everyday life. For example, the risks imposed in research involving human subjects focused on a special population should not be evaluated against the inherent risks encountered in their environment (e.g., emergency responder, pilot, soldier in a combat zone) or having a medical condition (e.g., frequent medical tests or constant pain).
3.26.2 In the case of Veterans Administration (VA) research, Non-Compliance is any failure to adhere to the requirements for overseeing, reviewing, approving, or conducting VA research set forth in law, regulation, policy, or study agreements (such as reliance agreements, memoranda of understanding, data use agreements), including any failure to conduct research in accordance with a VA study protocol approved by a research review committee.

3.27 Participating Site (pSite): An institution that participates in a Single IRB (sIRB) Study.

3.28 Prisoner: Any individual involuntarily confined or detained in a penal institution. The term is intended to encompass individuals sentenced to such an institution under a criminal or civil statute, individuals detained in other facilities by virtue of statutes or commitment procedures which provide alternatives to criminal prosecution or incarceration in a penal institution, and individuals detained pending arraignment, trial, or sentencing.

3.28.1 For Department of Defense (DOD) research the term includes military personnel in either civilian or military custody.

3.29 Protocol Exception: a one-time, intentional action or process that departs from the approved protocol. Protocol Exceptions are generally for a single subject (e.g., the subject does not meet eligibility criteria or is allergic to one of the medications provided as supportive care). IRB approval of the Protocol Exception is required prior to implementation by the study team.

3.30 Related to the Research: A financial interest is Related to the Research when the interest is in:

3.30.1 A sponsor of the research;
3.30.2 A competitor of the sponsor of the research;
3.30.3 A product or service being tested; or
3.30.4 A competitor of the product or service being tested.

3.31 Research as Defined by DHHS: A systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge.

3.31.1 The following activities are not considered Research as Defined by DHHS:

3.31.1.1 Scholarly and journalistic activities (e.g., oral history, journalism, biography, literary criticism, legal research, and historical scholarship), including the collection and use of information, that focus directly on the specific individuals about whom the information is collected.

3.31.1.2 Public health surveillance activities conducted by a public health authority, limited to those necessary to allow a public health authority to identify, monitor, assess, or investigate potential public health signals, onsets of disease outbreaks, or conditions of public health importance.

3.31.1.2.1 Including the collection and testing of information or biospecimens, conducted, supported, requested, ordered, required, or authorized by a public health authority.

3.31.1.2.2 Including trends, signals, risk factors, patterns in diseases, or increases in injuries from using consumer products.

3.31.1.2.3 Including those associated with providing timely situational awareness and priority setting during the course of an event or crisis that threatens public health (including natural or man-made disasters).

3.31.1.3 Collection and analysis of information, biospecimens, or records by or for a criminal justice agency for activities authorized by law or court order solely for criminal justice or criminal investigative purposes.

3.31.1.4 Authorized operational activities (as determined by the relevant federal agency) in support of intelligence, homeland security, defense, or other national security missions.

3.31.1.5 Secondary research involving non-identifiable newborn screening blood spots.

3.32 Research as Defined by FDA: Any experiment that involves a test article and one or more Human Subjects, and that meets any one of the following:
3.32.1 Must meet the requirements for prior submission to the Food and Drug Administration under section 505(i) of the Federal Food, Drug, and Cosmetic Act meaning any use of a drug other than the use of an approved drug in the course of medical practice;

3.32.2 Must meet the requirements for prior submission to the Food and Drug Administration under section 520(g) of the Federal Food, Drug, and Cosmetic Act meaning any activity that evaluates the safety or effectiveness of a device; OR

3.32.3 Any activity the results of which are intended to be later submitted to, or held for inspection by, the Food and Drug Administration as part of an application for a research or marketing permit.

3.33 Restricted: Applies to investigators who are delinquent in meeting IRB requirements.

3.34 Serious Adverse Event (SAE): An untoward occurrence, whether or not considered related to a subject’s participation in Human Research, that results in death, a life-threatening experience, inpatient hospitalization, prolongation of hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or that requires medical, surgical, behavioral, social or other intervention to prevent such an outcome.

3.35 Serious Non-Compliance: Non-Compliance such that the failure to comply could adversely affect the rights, safety, or welfare of a human subject; place a human subject at increased risk of harm; cause harm to a human subject; affect a human subject’s willingness to participate in research; or damage or compromise the scientific integrity of research data.

3.35.1 For Department of Defense (DOD) research Serious Non-Compliance includes failure of a person, group, or institution to act in accordance with Department of Defense (DOD) Instruction 3216.02 and its references such that the failure could adversely affect the rights, safety, or welfare of a human subject; place a human subject at increased risk of harm; cause harm to a human subject; affect a human subject’s willingness to participate in research; or damage or compromise the scientific integrity of research data.

3.35.2 For Veterans Administration (VA) research Serious Non-Compliance is any failure to adhere to requirements for conducting Human Research that may reasonably be regarded as:

3.35.2.1 Presenting a genuine risk of substantive harm, to the safety, rights, or welfare of human research subjects, research personnel, or others, including their rights to privacy and confidentiality of identifiable private information;

3.35.2.2 Presenting a genuine risk of substantive reputational harm to the Veterans Administration (VA); or

3.35.2.3 Substantively compromising a VA medical facility’s human research protection programs (HRPP).

3.36 Single IRB (sIRB) Study: A study in which two or more institutions (participating sites, or pSites) coordinate to complete the research activities, but all institutions rely on a single institution’s/organization’s IRB for ethical review. The reviewing IRB may or may not be affiliated with any of the pSites.

3.37 Suspension of IRB Approval: An action of the IRB, IRB designee, Institutional Official/Organizational Official, or designee of the Institutional Official/Organizational Official to temporarily or permanently withdraw IRB approval of some or all research procedures short of a Termination of IRB Approval. Suspended studies remain open and are subject to continuing review.

3.38 Systematic: Having or involving a system, method, or plan.


3.39.1 For Veterans Administration (VA) research, Termination of IRB Approval:
3.39.1.1 Refers to a permanent halt in all research activities due to concerns about the safety, rights, or welfare of human subjects, research personnel, or others, regardless of whether the action was taken by an investigator, facility official, research review committee, or external entity.

3.39.1.2 Does not refer to interruptions in research for other reasons, including the expiration of project approval periods.

3.40 Unanticipated Problem Involving Risks to Subjects or Others: Any information that is (1) unanticipated, (2) related to the research, and (3) indicates that subjects or others are at increased risk of harm.

3.40.1 For Department of Defense (DOD) research the term Unanticipated Problem Involving Risks to Subjects or Others includes any incident, experience, or outcome that meets ALL three of the following conditions:

3.40.1.1 Is unexpected (in terms of nature, severity, or frequency) given the procedures described in the research protocol documents (e.g., the IRB-approved research protocol and informed consent document) and the characteristics of the human subject population being studied.

3.40.1.2 Is related or possibly related to participation in the research (in this Instruction, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research).

3.40.1.3 Suggests that the research places human subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized, even if no harm has actually occurred.

3.40.2 For Veterans Administration (VA) research:

3.40.2.1 Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO) is an incident, experience or outcome that is: unexpected; related or possibly related to participation in the research; and indicative of the research placing subjects or others at substantively greater risk of harm (including physical, psychological, economic or social harm) than was previously known or recognized.

3.40.2.2 The term “unexpected” refers to an incident, experience, or outcome that is new or greater than previously known in terms of nature, severity, or frequency, given the procedures described in protocol-related documents and the characteristics of the study population.

3.40.2.3 The phrase “related to participation in the research” means a logical sequence of cause and effect shows that the study procedures were the reason for the incident, experience, or outcome. The phrase “possibly related to participation in the research” implies a lesser degree of certainty about causality and refers to an incident, experience, or outcome for which there is some evidence to reasonably suggest a causal relationship between study procedures and the incident, experience, or outcome.

3.40.2.4 An unexpected SAE that is related or possibly related to participation in human subjects research constitutes a UPIRTSO.

4 RESPONSIBILITIES

4.1 Individuals writing policies and procedures are to indicate terms defined in this policy with a double underline.

4.2 Individuals using policies and procedures are to consult this policy for the definitions of double underlined terms.

5 PROCEDURE
5.1 None

6 MATERIALS

6.1 HRP-013 - SOP - LARs, Children, and Guardians

7 REFERENCES

7.1 45 CFR §46.102.
7.2 21 CFR §50.3, 21 CFR §56.102, 21 CFR §312.3, 21 CFR §812.2(a), 21 CFR §812.3(p)
7.3 VHA Handbook 1058.01 dated October 22, 2020; VHA Directive 1004.08 dated October 31, 2018; VHA Directive 1200.05 dated January 7, 2019, amended January 8, 2021; VHA Directive 1058.03 dated September 17, 2020
1 PURPOSE

1.1 This procedure establishes the process to observe the consent process.
1.2 The process begins when the IRB determines that the consent process should be observed.
1.3 The process ends when the IRB determines that the consent process no longer should be observed.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 The IRB may consider observation of the consent process when:
   3.1.1 The IRB wants verification from sources other than the investigator that no material changes have taken place since prior IRB review.
   3.1.2 There are Allegations or Findings of Non-Compliance.
   3.1.3 The nature of the research indicates that the consent process can be improved through observation.

3.2 The IRB, Institutional Official/ Organizational Official (IO/OO), or designee designates who conducts the observation. The IRB may have the observation conducted by:
   3.2.1 IRB staff.
   3.2.2 IRB members.
   3.2.3 A person recommended by the investigator.
   3.2.4 An independent person hired by the IRB, but paid for by the investigator’s funds.

4 RESPONSIBILITIES

4.1 The person designated to conduct the observation of the consent process carries out these procedures.

5 PROCEDURE

5.1 Observe the consent process and determine whether the information in the consent document and any other written information was accurately explained to, and apparently understood by, the subject or the subject’s Legally Authorized Representative (LAR), and that informed consent was freely given by the subject or the LAR.
   5.1.1 If no, indicate that consent is not legally effective and the prospective subject may not be entered into the research.
   5.1.2 If yes, document in writing that the consent process was observed and that informed consent was freely given by the subject or LAR.

6 MATERIALS

6.1 None

7 REFERENCES

7.1 None
1 PURPOSE

1.1 This policy establishes how to determine which individuals meet the following DHHS and FDA definitions:

1.1.1 Legally Authorized Representative
1.1.2 Children
1.1.3 Guardian

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 Unless the IRB has waived the requirement to obtain consent, when research involves adults unable to consent, permission must be obtained from a Legally Authorized Representative.

3.1.1 When research is conducted in Massachusetts the following individuals meet this definition:

3.1.1.1.1 Health care agent. Massachusetts law provides for proxy consent for medical decisions to be given on behalf of an individual who does not have the capacity to consent. The law allows a competent adult to appoint a designated person as his or her “health care agent.” M.G.L. c. 201D. If the person then becomes incapacitated, and is in need of medical care, the health care proxy becomes empowered to make medical decisions on his or her behalf. If no health care agent has been appointed in advance, then medical care providers are authorized by the law to accept consent from “responsible parties,” under common law principles, usually meaning the individual’s next-of-kin. M.G.L. c. 201D, §16. It is generally accepted in Massachusetts that if research involves the provision of medical care, a health care agent, whether appointed or holding that status by virtue of being a “responsible party,” may consent to that treatment and to the accompanying research.

3.1.1.1.2 Guardian. Under Massachusetts law, a guardian is an individual, organization or agency, if any, that has been appointed legal guardian of the person found to be incompetent by a court of competent jurisdiction.

3.1.2 For all other research conducted in Massachusetts, the Office of the General Counsel shall be consulted to determine whether or not the individuals proposed to serve as legally authorized representatives are considered Legally Authorized Representatives.

3.1.2 For research outside Massachusetts, a determination of who is a Legally Authorized Representative is to be made with consultation from the Office of the General Counsel.

3.2 DHHS and FDA’s Subpart D applies to all research involving children.

3.2.1 When research is conducted in Massachusetts, all individuals under the age of 18 years are children. Exceptions exist for:

3.2.1.1 Emancipated minors, defined as individuals who meet one of the following criteria:

3.2.1.1.1 Married/widowed/divorced individual;
3.2.1.1.2 A parent;
3.2.1.1.3 A member of the armed forces;
3.2.1.1.4 An individual living apart from parents and managing his or her own finances; or
3.2.1.1.5 A female who is pregnant or believes herself to be pregnant, unless the procedures involved in the research include abortion as described in 3.2.3 below.

3.2.2 Individuals under the age of 18 when the research procedures are limited to:
3.2.2.1 Diseases dangerous to the public health;
3.2.2.2 Drug dependency (other than alcohol dependency)
3.2.2.3 Pregnancy, unless the procedures involved in the research include abortion as described in 3.2.3 below.

3.2.3 Exception: If the research procedures involve abortion, a female under the age of 18 who is not and has never been married meets the definition of children.
3.2.4 Contact the Office of the General Counsel for more information.
3.2.5 For research outside Massachusetts, a determination of who is a child is to be made with consultation from the Office of the General Counsel.

3.3 Individuals who can document that they are legally authorized to consent on behalf of the child to general medical care may serve as a guardian. Under Massachusetts law, a child’s guardian is an individual, organization or agency, if any, that has been appointed through a court process as legal guardian for that child. For research conducted outside of Massachusetts, the Office of the General Counsel shall be consulted to determine who meets the definition of guardian for a child. Before obtaining permission for a child to take part in research from someone who is not a parent, contact the Office of the General Counsel.

4 RESPONSIBILITIES
4.1 Investigators are to follow this policy when obtaining permission for adults unable to consent or children to take part in research.

5 PROCEDURE
5.1 None

6 MATERIALS
6.1 None

7 REFERENCES
7.1 45 CFR §46.102, 45 CFR §46.402
7.2 21 CFR §50.3
1 PURPOSE

1.1 This procedure establishes the process to triage information submitted to the IRB.
1.2 The process begins when any communication is received by the IRB.
1.3 The process ends when an IRB staff member determines the appropriate action for the received information.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None.

3 POLICY

3.1 None

4 RESPONSIBILITIES

4.1 IRB staff members carry out these procedures.

5 PROCEDURE

5.1 If the item is a request either for this IRB to review for another Participating Site (pSite) or for this institution to rely on an external IRB, follow HRP-803 - SOP - Reliance Pre-Review.
5.2 If the item is a request for an approval or determination\(^1\) by this institution's IRB that does not include other pSites, follow HRP-021 - SOP - Pre-Review.
5.3 If the item is an update to a study for which an external IRB is the IRB of record, follow HRP-805 - SOP - External IRB Updates.
5.4 If the item includes new or modified contact information, update the contact information.
5.5 If the item includes new or modified training information, update the training information.
5.6 If the item includes an updated list of study personnel:
   5.6.1 Send HRP-524 - LETTER - Ack Personnel Update.
   5.6.2 If there are financial disclosures, follow HRP-055 - SOP - Financial Conflicts of Interests.
5.7 If the item is a notification of an emergency use of a test article in a life-threatening situation have a Designated Reviewer follow HRP-023 - SOP - Emergency Use, Compassionate Use, Indiv Patient Expanded Access.
5.8 If the item is an investigator's request to continue subjects in expired research have a Designated Reviewer follow "SOP: Expiration of IRB Approval (HRP-063)."
5.9 If the item does not fit into the above categories:
   5.9.1 If the item is a question, concern, or complaint:
      5.9.1.1 Document the nature of the question, concern, or complaint and the contact information of the person contacting the IRB.
      5.9.1.2 Respond to any questions or concerns. When appropriate, tell the person that you will call/email him/her once you have been able to find additional information. If necessary, consult with your supervisor.
   5.9.2 Follow "SOP: New Information (HRP-024)."

6 MATERIALS

6.1 HRP-021 - SOP - Pre-Review

---

\(^1\) A “request for an approval or determination” includes approval of new research, response to modifications required to secure approval, continuing review of research, modification to previously approved research, request for study closure, or a determination whether an activity is exempt Human Research or is not Human Research. Submission of an updated list study personnel is not considered a modification of research and is therefore not a “request for an approval or determination.”
6.2 HRP-023 - SOP - Emergency Use, Compassionate Use, Indiv Patient Expanded Access
6.3 HRP-024 - SOP - New Information
6.4 HRP-055 - SOP - Financial Conflicts of Interests
6.5 HRP-063 - SOP - Expiration of IRB Approval
6.6 HRP-524 - LETTER - Ack Personnel Update
6.7 HRP-803 - SOP - Reliance Pre-Review
6.8 HRP-805 - SOP - External IRB Updates

7 REFERENCES

1 PURPOSE

1.1 This procedure establishes the process to pre-review a request for approval (approval of new research, humanitarian use device (HUD), continuing review of research, or modification to previously approved research) or a determination whether an activity is exempt Human Research or is not Human Research.

1.2 The process begins when the IRB receives a request for local IRB approval, including requests from other institutions when this institution is the IRB of record, e.g., for a Collaborative Study or Multi-Site Study.

1.3 The process ends when the information has been placed on the agenda for an IRB meeting or will be handled by Non-Committee Review.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None.

3 POLICY

3.1 The addition of a participating site to a previously approved protocol for which the IRB will serve as the IRB of record for that participating site is considered a modification to previously approved research.

3.2 Single subject protocol exceptions are reviewed as modifications to previously approved research.¹

3.3 A new HUD protocol submission must be reviewed at a convened IRB meeting. Continuing review of a HUD can be handled by Non-Committee Review.

4 RESPONSIBILITIES

4.1 IRB staff members carry out these procedures.

5 PROCEDURE

5.1 If the submission is a response to modifications required to secure approval received within 90 days of the IRB review date:

5.1.1 Evaluate whether the investigator made the required modifications.

5.1.2 If the investigator made the required modifications, follow HRP-052 - SOP - Post-Review to issue an approval.

5.1.3 If the investigator did not make the required modifications or made unrequested modifications, contact the investigator. Offer the investigator the opportunity to correct the submission.

5.1.3.1 If the investigator will correct the submission, have the investigator resubmit and stop processing the current submission.

5.1.3.2 If the investigator will not correct the submission, continue processing.

5.2 For all other submissions, complete HRP-401 - CHECKLIST - Pre-Review or review the previously completed HRP-401 - CHECKLIST - Pre-Review and revise as needed, considering the items on HRP-308 - WORKSHEET - Pre-Review and note all remaining contingencies in the “Final Contingencies” section.

5.3 If the request is for an initial approval and principal investigator is Restricted, contact the investigator. Explain that the investigator is Restricted, give the reasons, and indicate that if a new protocol goes to the IRB, the IRB policy is to disapprove the research. Offer the investigator the opportunity to withdraw the submission pending removal of the Restricted status.

5.3.1 If the investigator withdraws the submission, stop processing the current submission.

¹ Per OHRP correspondence dated 07/22/2011, protocol exceptions are considered changes to previously approved research and eligible for review via expedited procedure.
5.3.2 If the investigator will not withdraw the submission, discuss whether you may continue to process the submission with the IRB Chair.

5.4 Evaluate the most likely level of review using HRP-310 - WORKSHEET - Human Research Determination, HRP-311 - WORKSHEET - Engagement Determination, HRP-312 - WORKSHEET - Exemption Determination, HRP-313 - WORKSHEET - Expedited Review, and/or HRP-323 - WORKSHEET - Criteria for Approval HUD as references::

5.4.1 If the study can be closed, complete and send HRP-511 - LETTER – Closure.

5.4.2 If the request can be handled as a Non-Committee Review and the principal investigator is not Restricted, Follow HRP-031 - SOP - Non-Committee Review Preparation.

5.4.3 If the request cannot be handled as a Non-Committee Review, place the protocol on the agenda for a convened IRB meeting in an IRB with appropriate scope. (Do not assign a Veterans Administration (VA) protocol to a commercial IRB unless it has been specifically designated by the VA Office of Research and Development to serve as an IRB for cooperative research.)

5.4.4 If the request is a non-emergency individual patient expanded access use of an investigational drug for which an IRB waiver is requested, follow HRP-031 - SOP - Non-Committee Review Preparation and HRP-023 - SOP - Emergency Use, Compassionate Use, Indiv Patient Expanded Access.

6 MATERIALS

6.1 HRP-023 - SOP - Emergency Use, Compassionate Use, Indiv Patient Expanded Access
6.2 HRP-024 - SOP - New Information
6.3 HRP-031 - SOP - Non-Committee Review Preparation
6.4 HRP-040 - SOP - IRB Meeting Preparation
6.5 HRP-052 - SOP - Post-Review
6.6 HRP-308 - WORKSHEET - Pre-Review
6.7 HRP-310 - WORKSHEET - Human Research Determination
6.8 HRP-311 - WORKSHEET - Engagement Determination
6.9 HRP-312 - WORKSHEET - Exemption Determination
6.10 HRP-313 - WORKSHEET - Expedited Review
6.11 HRP-323 - WORKSHEET - Criteria for Approval HUD
6.12 HRP-401 - CHECKLIST - Pre-Review
6.13 HRP-511 - LETTER - Closure

7 REFERENCES


---

2 Refer to the VA application process for the use of a commercial IRB approved by ORD: https://www.research.va.gov/programs/orppe/single_irb.cfm
1 PURPOSE

1.1 This procedure establishes the process to review notifications of:

1.1.1 Emergency use of a drug, biologic, or device in a life-threatening situation.
1.1.2 Non-emergency individual patient/small group expanded access for an unapproved medical device (commonly known as Compassionate Use).
1.1.3 Non-emergency individual patient expanded access use of an investigational drug for which an IRB waiver is requested.

1.2 The process begins when the IRB receives a notification of a proposed or actual use.
1.3 The process ends when a Designated Reviewer has:

1.3.1 Determined whether the proposed or actual use will follow or has followed FDA-regulation and guidance; and
1.3.2 Notified the physician and IRB staff of the determination.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 Whenever possible physicians are to notify the IRB of a proposed emergency use of a drug, biologic, or device in a life-threatening situation in advance of the use.
3.2 Physicians are to notify the IRB of a proposed compassionate use of an unapproved device, for the purpose of obtaining concurrence from an IRB Chair.
3.3 Emergency uses and device compassionate uses cannot be claimed as research.
3.4 Investigators are to notify the IRB of a non-emergency individual patient expanded access use of an investigational drug “Request for Authorization to Use Alternative IRB Review Procedures” identified on FDA Form 3926 (field 10.b.) or a separate waiver request included with FDA Form 1571 for the purpose of obtaining concurrence from an IRB Chair or designee.

4 RESPONSIBILITIES

4.1 A Designated Reviewer carries out these procedures.

5 PROCEDURE

5.1 Determine if the notification/request is one of the following:

5.1.1 Emergency use of a drug, biologic, or device in a life-threatening situation. If so, use the HRP-322 - WORKSHEET - Emergency Use to determine whether the circumstances will meet, or if the use described in the 5-day report have met, the regulatory and guidance criteria for emergency use, and indicate the results of this determination to the IRB staff (or directly to the physician if time sensitive).

5.1.1.1 If the notice is in advance of the use, inform the IRB staff (or physician if time sensitive) that the physician can proceed with the use or work with the physician to identify what additional information/procedures the physician needs to follow. Set a 5-day reminder to request the 5-day report.

5.1.1.2 If the actual emergency use described in the 5-day report did not follow FDA requirements, manage use HRP-024 - SOP - New Information as Non-Compliance.

5.1.2 Compassionate use of a device. If so, use HRP-325 - WORKSHEET - Device Compassionate Use to determine whether the circumstances will meet the regulatory and guidance criteria and indicate the results of this determination to the physician.
5.1.3 Non-emergency individual patient expanded access use of an investigational drug for which an IRB waiver is requested. If so, use HRP-314 - WORKSHEET - Criteria for Approval to determine whether the proposed use meets the requirements under 21 CFR 50 and 56.1111 and indicate the results of this determination to the IRB staff.

5.1.3.1 Execute the “Submit Designated Review” activity. In the “Notes” section document that the decision is to concur (or not) is in lieu of review and approval at a convened IRB meeting at which a majority of the members are present per the request for a waiver under 21 § 56.105 of the requirements in § 56.108(c).

5.1.4 If none of the above, stop processing the request and inform the physician or submitter.

5.2 Inform IRB staff of the results of the evaluation.

6 MATERIALS

6.1 HRP-024 - SOP - New Information
6.2 HRP-314 - WORKSHEET - Criteria for Approval
6.3 HRP-322 - WORKSHEET - Emergency Use
6.4 HRP-325 - WORKSHEET - Device Compassionate Use

7 REFERENCES

7.1 21 CFR §50.23; 21 CFR §50.24; 21 CFR §56.102(d); 21 CFR §56.104(c).
7.2 21 CFR §812.36; 21 CFR §812.47.
7.3 21 CFR § 56.105; 21 CFR § 56.108(c).

---

1 “The IRB chairperson (or designated IRB member) would consider the same information that the full IRB would consider to determine whether to approve the treatment when reviewing and concurring for individual patient expanded access use.” Per FDA correspondence dated 10/10/17
1 PURPOSE

1.1 This procedure establishes the process to manage information reported to the IRB to ensure that information that represents Non-Compliance, Unanticipated Problems Involving Risks to Subjects or Others, Suspensions of IRB Approval, and Terminations of IRB Approval are managed to protect the rights and welfare of subjects.

1.2 The process begins when the IRB receives an information item.

1.3 The process ends when the information item is determined not to represent a problem that requires management, is managed administratively, or referred to the convened IRB for review.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None.

3 POLICY

3.1 Allegations of Serious or Continuing Non-Compliance on the part of IRB staff or IRB members will be referred to the Organizational Official for further action.

3.2 The organization will promptly notify the federal department or agency funding the research of any for cause investigation of that research by another federal department or agency or national organization.

3.2.1 For Department of Defense (DOD) research the report is sent to the DOD human research protection officer.

3.3 The organization will promptly notify the Department of Defense (DOD) if the IRB of record changes.

3.4 For Veterans Administration (VA) research:

3.4.1 The determination that Non-Compliance is Serious Non-Compliance or Continuing Non-Compliance must be determined and documented by the convened IRB.

3.4.2 The convened IRB must review notifications of apparent Unanticipated Problems Involving Risks to Subjects or Others, Serious Non-Compliance, Continuing Non-Compliance, and external Suspension of IRB Approval, or Termination of IRB Approval within 30 calendar days after receiving the notification.

3.4.3 The IRB Chair may take interim action on notifications of apparent Unanticipated Problems Involving Risks to Subjects or Others, Serious Non-Compliance or Continuing Non-Compliance as needed to eliminate apparent immediate hazards to subjects.

3.4.4 An apparent unexpected Serious Adverse Event (SAE) that is related or possibly related to participation in human subjects research constitutes an apparent Unanticipated Problems Involving Risks to Subjects or Others.

3.4.5 Except where remediation requires substantial renovation or fiscal expenditure, hiring, legal negotiations, or other extenuating circumstances, remedial actions must be completed within 180 calendar days after any determination of Non-Compliance.

4 RESPONSIBILITIES

4.1 The IRB staff members carry out this procedure.

5 PROCEDURE

5.1 Review each item of information and answer the following questions and complete the “For IRB Use Only” section of HRP-214 - FORM - Reportable New Information: (See attached flowchart for a diagram of the flow of this procedure.)

5.1.1 Is this an Allegation of Non-Compliance?

5.1.2 Is this a Finding of Non-Compliance?

5.1.3 Is this an Unanticipated Problem Involving Risks to Subjects or Others?

5.1.4 Is this a Suspension of IRB Approval or Termination of IRB Approval?

5.2 If you are unable to answer a question, consult the IRB chair or IRB manager.
5.3 If the IRB chair and IRB manager are unable to answer a question, follow HRP-025 - SOP - Investigations.

5.4 If the answer is "yes" to one or more questions, then follow the corresponding sections below.

5.4.1 Allegations of Non-Compliance: Determine whether each Allegation of Non-Compliance has any basis in fact.

5.4.1.1 If yes, follow the procedures under Findings of Non-Compliance.

5.4.1.2 If no, follow any other corresponding sections.

5.4.2 Findings of Non-Compliance: Determine whether each Finding of Non-Compliance is Serious Non-Compliance or Continuing Non-Compliance.

5.4.2.1 If no, follow the procedures under Non-Serious/Non-Continuing Non-Compliance.

5.4.2.2 If yes, follow the procedures under Serious or Continuing Non-Compliance.

5.4.3 Non-Serious/Non-Continuing Non-Compliance

5.4.3.1 Work with the individual or group responsible for the Non-Compliance to develop and implement a suitable corrective action plan.

5.4.3.2 If unable to work with the individual or group responsible for the Non-Compliance to develop and implement a suitable corrective action plan, consider the Non-Compliance to be Continuing Non-Compliance and follow the procedures for Serious or Continuing Non-Compliance.

5.4.4 Serious Non-Compliance; Continuing Non-Compliance; Suspension of IRB Approval; Termination of IRB Approval; or Unanticipated Problem Involving Risks to Subjects or Others

5.4.4.1 If the notification involves enrollment of a Prisoner in a study not approved to enroll Prisoners, please see below for additional considerations to aid in decision-making.

5.4.4.2 Confirm your decision with the IRB chair or IRB manager.

5.4.4.3 Place on the agenda for the next available convened IRB meeting in an IRB with appropriate scope as an item of Serious Non-Compliance; Continuing Non-Compliance; Suspension of IRB Approval; Termination of IRB Approval; or Unanticipated Problem Involving Risks to Subjects or Others.

5.5 If in your opinion the rights and welfare of subjects might be adversely affected before the convened IRB can review the information, contact the IRB chair or IRB manager to consider a Suspension of IRB Approval following the HRP-026 - SOP - Suspension or Termination Issued Outside of Convened IRB.

5.6 If the notification involves a subject becoming a Prisoner in a study not approved by the IRB to involve Prisoners:

5.6.1 Confirm that the subject is currently a Prisoner.

5.6.1.1 If the subject is currently not a Prisoner no other action is required.

5.6.2 Consider whether stopping all research interactions and interventions with, and obtaining identifiable private information about, the now-incarcerated subject until the regulatory requirements for research involving Prisoners are met or until the subject is no longer a Prisoner would present risks to the subject.

5.6.2.1 If the subject’s involvement in the research cannot be stopped for health or safety reasons, do one of the following:

5.6.2.1.1 Keep the subject enrolled in the study and review the research for involvement of Prisoners. If the research is subject to DHHS oversight, notify OHRP.

5.6.2.1.2 Remove the subject from the study and provide the study intervention as clinical care or compassionate use.

5.6.2.2 If the subject’s involvement in the research can be stopped, inform the investigator that all research interactions and interventions with, and
obtaining identifiable private information about the now-incarcerated subject must be stopped immediately until the regulatory requirements for research involving Prisoners are met or until the subject is no longer a Prisoner.

5.6.3 For Department of Defense (DOD) research, have the convened IRB promptly (within 30 days) re-review the research protocol to ensure that the rights and well-being of the human subject, now a prisoner, are not in jeopardy.

5.6.3.1 Promptly report all decisions to the Department of Defense (DOD).

5.6.3.2 The Department of Defense (DOD) must concur with the IRB before the subject can continue to participate while a prisoner.

5.7 For AAHRPP accredited organizations only: If the information involves any of the following, complete and send HRP-529 - LETTER - AAHRPP Notice of Information Item to AAHRPP as soon as possible but generally within two days of the receipt of the information, in addition to other applicable procedures listed in this SOP:

5.7.1 Negative actions by a government oversight office, including, but not limited to, OHRP Determination Letters, FDA Warning Letters, FDA 483 Inspection Reports with official action indicated, FDA Restrictions Placed on IRBs or Investigators, and corresponding compliance actions taken under non-US authorities related to human research protections.

5.7.2 Litigation, arbitration, or settlements initiated related to human research protections.

5.7.3 Press coverage (including but not limited to radio, TV, newspaper, online publications) of a negative nature regarding the Organization’s HRPP.

5.8 Take any additional actions required to resolve any concerns or complaints associated with the information.

5.9 For Veterans Administration (VA) research:

5.9.1 If the information represents an Unanticipated Problem Involving Risks to Subjects or Others that is a local research death:

5.9.1.1 Within one (1) business day after receiving written notification of the death, the IRB Chair or Designated Reviewer must assess and document whether any actions are warranted to eliminate apparent immediate hazards to subjects and, if so, initiate those actions.

5.9.1.2 Schedule the written notification, the immediate hazard assessment of the IRB Chair or Designated Reviewer, and the actions taken to date for the next convened IRB meeting, not to exceed 30 calendar days after the date of written notification. NOTE: This may require the IRB to convene an emergency session prior to its next scheduled meeting.

5.9.1.3 The IRB must determine and document within 30 calendar days of the convened IRB’s initial review:

5.9.1.3.1 Whether the death was both unexpected and related or possibly related to participation in the research; and

5.9.1.3.2 What, if any, protocol or informed consent modifications are warranted. If modifications are warranted, the convened IRB must determine and document whether or not investigators must notify or solicit renewed/revised consent from previously enrolled subjects; and if so, when such notification or consent must take place and how it must be documented.

5.9.2 Within 5 business days of receipt of written notification of information that appears to represent an Unanticipated Problem Involving Risks to Subjects or Others, have the IRB Chair or a Designated Reviewer determine and document whether any actions are warranted to eliminate apparent immediate hazards to subjects (and if so, initiate those actions).

5.9.2.1 Schedule the written notification, the immediate hazard assessment of the IRB Chair or Designated Reviewer, and the actions taken to date for the
next convened IRB meeting, not to exceed 30 calendar days after the date of written notification (this may require the IRB to convene an emergency session prior to its next scheduled meeting).

5.9.2.1.1 If the IRB determines that the problem or event is unexpected and related to or possibly related to participation in the research and indicative of the research placing subjects or others at substantively greater risk of harm than was previously known or recognized (i.e., whether the incident, experience or outcome constituted an actual Unanticipated Problem Involving Risks to Subjects or Others), the IRB must report in writing its determinations within 5 business days to:

5.9.2.1.1.1 VA Medical Facility Director.
5.9.2.1.1.2 ACOS/R&D.
5.9.2.1.1.3 The Research Compliance Officer (RCO).

5.9.3 If the information appears to represent Serious Non-Compliance or Continuing Non-Compliance, schedule the information for the next IRB meeting to be reviewed by the convened IRB, not to exceed 30 calendar days after the date of written notification (this may require the IRB to convene an emergency session prior to its next scheduled meeting).

5.9.4 If the IRB determines that the information constitutes Serious Non-Compliance or Continuing Non-Compliance, the IRB must report in writing its determinations within 5 business days to:

5.9.4.1.1 VA Medical Facility Director.
5.9.4.1.2 ACOS/R&D.
5.9.4.1.3 The RCO.

5.10 If the information does not involve a Serious Non-Compliance; Continuing Non-Compliance; Suspension of IRB Approval; Termination of IRB Approval; or Unanticipated Problem Involving Risks to Subjects or Others and a response is expected, complete and send a HRP-519 - LETTER - Information Item to the person submitting the information.

6 MATERIALS

6.1 HRP-025 - SOP – Investigations
6.2 HRP-026 - SOP - Suspension or Termination Issued Outside of Convened IRB
6.3 HRP-052 - SOP - Post-Review
6.4 HRP-214 - FORM - Reportable New Information
6.5 HRP-519 - LETTER - Information Item
6.6 HRP-529 - LETTER - AAHRPP Notice of Information Item

7 REFERENCES

7.1 21 CFR §56.108(b)
7.2 45 CFR §46.103(b)(5), 45 CFR §46.108(a)
7.3 VHA Directive 1058.01 October 22, 2020
7.5 Flowchart

New Information

Ask all four questions

- Allegation of Non-compliance?
  - Yes
    - Does allegation have a basis in fact?
      - Yes
        - Manage Administratively
      - No
        - Unable to achieve a collaborative outcome?
          - Yes
            - Report to regulatory agencies and appropriate institutional officials
          - No

- Finding of Non-compliance?
  - Yes
    - Is Non-compliance Serious or Continuing?
      - Yes
        - Consider Interim Actions
      - No

- Unanticipated Problem Involving Risk to Subjects or Others?
  - Yes

- Suspension or Termination of IRB Approval?
  - Yes

Stop if ALL paths lead to “No” answers
1 PURPOSE

1.1 This procedure establishes the process to conduct investigations.
1.2 The process begins when the IRB staff members and chair cannot answer a question required by “SOP: New Information (HRP-024).”
1.3 The process ends when the investigation is complete and the answer has been provided to the Institutional Official/Organizational Official (IO/OO) or designee.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None.

3 POLICY

3.1 None

4 RESPONSIBILITIES

4.1 The IO/OO or designee:
   4.1.1 Appoints the members of the investigative committee based on the expertise and background needed to answer the question.
   4.1.2 Appoints a chair of the investigative committee.
   4.1.3 Charges the investigative committee with the question to be answered.
4.2 The investigative committee carries out these procedures within 60 days.
4.3 Investigative committee members make their decisions based on a preponderance of the evidence.
4.4 Investigative committee decisions are made by majority vote.
4.5 Individuals being interviewed may have counsel present. However, counsel cannot address the investigative committee. The investigative committee by a vote of the majority may exclude counsel when in the opinion of the investigative committee that person’s presence is disruptive.

5 PROCEDURE

5.1 Notify the investigator that an investigation is being conducted, the question to be answered, and the time frame for completion.
5.2 Determine what information to gather and what individuals to interview.
5.3 Gather information and interview individuals.
5.4 If the investigative committee believes that a transcription of the interviews will be required to make a proper decision, the investigative committee may request a court stenographer to record all interviews.
5.5 Repeat information gathering and interviews until a decision can be made.
5.6 The investigative committee provides a written report of the investigative committee’s decision to the IO/OO or designee.

6 MATERIALS

6.1 SOP: New Information (HRP-024)

7 REFERENCES

7.1 None
SOP: Suspension or Termination

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>DATE</th>
<th>AUTHOR</th>
<th>APPROVED BY</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRP-026</td>
<td>12/10/2021</td>
<td>M. Williams</td>
<td>M. Meyer</td>
<td>1 of 2</td>
</tr>
</tbody>
</table>

1 PURPOSE
1.1 This procedure establishes the process for someone other than the convened IRB to institute a Suspension of IRB Approval or a Termination of IRB Approval.
1.2 The process begins when the Organizational Official / Institutional Official (IO/OO) or designee institutes a Suspension of IRB Approval or a Termination of IRB Approval.
1.3 The process ends when the Suspension of IRB Approval or a Termination of IRB Approval has been placed on the agenda for review by the convened IRB.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None.

3 POLICY
3.1 The IRB chair or IRB manager may institute a Suspension of IRB Approval when in the opinion of the IRB chair or IRB manager subjects may be at risk of adverse effects on their rights and welfare before action may be considered by the convened IRB.
3.2 The IO/OO or designee may institute a Suspension of IRB Approval or Termination of IRB Approval for any reason.
3.2.1 For Veterans Administration (VA) research, this authority may be delegated by the IO to the Chief of Staff (COS). ORD has authority to suspend or terminate any research activity it is funding.
3.3 Whenever possible the individual following these procedures communicates with investigators orally and in writing.

4 RESPONSIBILITIES
4.1 The individual instituting a Suspension of IRB Approval or Termination of IRB Approval follows these procedures.

5 PROCEDURE
5.1 Notify the investigator of the Suspension of IRB Approval or Termination of IRB Approval along with the reasons for the decision.
5.2 Ask the investigator for a list of Human Subjects currently involved in the research.
5.3 Ask the investigator whether any actions are required to protect those subjects’ rights and welfare or to eliminate an apparent immediate hazard.
5.4 Consider whether any of the following additional actions are required to protect those or other subjects rights and welfare or to eliminate an apparent immediate hazard:
   5.4.1 Transferring subjects to another investigator.
   5.4.2 Making arrangements for clinical care outside the research.
   5.4.3 Allowing continuation of some research activities under the supervision of an independent monitor.
   5.4.4 Requiring or permitting follow-up of subjects for safety reasons.
   5.4.5 Requiring adverse events or outcomes to be reported to the IRB and the sponsor.
   5.4.6 Notification to current Human Subjects.
   5.4.7 Notification to former Human Subjects.
5.5 For Veterans Administration (VA) research, report the Suspension of IRB Approval or Termination of IRB Approval to the VA facility Director, the Associate Chief of Staff/R&D, and RCO within 5 business days of the determination(s). The notification must include a statement of the reason for the action.
5.6 Refer to the IRB staff to place on the agenda for a convened IRB meeting in an IRB with appropriate scope as an item of Suspension of IRB Approval or Termination of IRB Approval. Follow “SOP: IRB Meeting Conduct (HRP-041)” for convened IRB review of the item
5.7 Complete and send to the investigator a “TEMPLATE LETTER: Suspension or Termination (HRP-515).”

6 MATERIALS
6.1 HRP-041 - SOP - IRB Meeting Conduct
6.2 HRP-515 - LETTER - Suspension or Termination

7 REFERENCES

7.1 21 CFR §56.108(b)(3), 21 CFR §56.113
7.2 45 CFR §46.103(b)(5)(ii), 45 CFR §46.108(a), 45 CFR §46.113
7.3 VHA Directive 1058.01 October 22, 2020
1 PURPOSE
1.1 This procedure establishes the process to communicate the review of:

1.1.1 Emergency use of a drug, biologic, or device in a life-threatening situation.
1.1.2 Non-emergency individual patient/small group expanded access for an unapproved medical device (commonly known as Compassionate Use).
1.1.3 Non-emergency individual patient expanded access use of an investigational drug for which an IRB waiver is requested.

1.2 The process begins when the Designated Reviewer has notified IRB staff of whether an actual or proposed use has followed or will follow FDA regulations and guidance.
1.3 The process ends when the IRB staff has communicated the results to the physician and, if necessary, initiated the non-compliance process.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 None.

4 RESPONSIBILITIES
4.1 IRB staff carry out these procedures.

5 PROCEDURE
5.1 For emergency use of a drug, biologic, or device in a life-threatening situation:
5.1.1 If the Designated Reviewer has indicated that the proposed use will follow FDA regulations:
5.1.1.1 Complete a “TEMPLATE LETTER: Pre-Review of Emergency Use - Criteria Met (HRP-570)” and send to the physician.
5.1.1.2 Set a 5 day deadline for receipt of the 5 day report.
5.1.2 If the Designated Reviewer has indicated that the proposed use will NOT follow FDA regulations, complete a “TEMPLATE LETTER: Pre-Review of Emergency Use - Criteria Not Met (HRP-571)” and send to the physician.
5.1.3 If the Designated Reviewer has indicated that the actual use described in the 5-day report followed FDA regulations, complete a “TEMPLATE LETTER: Review of Emergency Use - Criteria Met (HRP-572)” and send to the physician.
5.1.4 If the Designated Reviewer has indicated that the proposed use did NOT follow FDA regulations:
5.1.4.1 Complete a “TEMPLATE LETTER: Review of Emergency Use - Criteria Not Met (HRP-573)” and send to the physician.
5.1.4.2 Manage under “SOP: New Information (HRP-024)” as Non-Compliance.

5.2 For compassionate use of a device, complete a “TEMPLATE LETTER: Review of Device Compassionate Use (HRP-574).”

5.3 For non-emergency individual patient expanded access use of an investigational drug for which an IRB waiver is requested, complete “TEMPLATE LETTER: Review of IRB Waiver for Non-Emergency Individual Patient Expanded Access Use of an Investigational Drug (HRP-575).”

6 MATERIALS
6.1 SOP: New Information (HRP-024)
6.2 TEMPLATE LETTER: Pre-Review of Emergency Use - Criteria Not Met (HRP-571)
SOP: All Emergency Use, Compassionate Use (Device Only) and IRB Waiver for Individual Patient Expanded Access (Drug Only) Post-Review

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>DATE</th>
<th>AUTHOR</th>
<th>APPROVED BY</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRP-027</td>
<td>11/30/18</td>
<td>M. Williams</td>
<td>M. Meyer</td>
<td>2 of 2</td>
</tr>
</tbody>
</table>

6.3 TEMPLATE LETTER: Review of Emergency Use - Criteria Met (HRP-572)
6.4 TEMPLATE LETTER: Review of Emergency Use - Criteria Not Met (HRP-573)
6.5 TEMPLATE LETTER: Pre-Review of Emergency Use - Criteria Met (HRP-570)
6.6 TEMPLATE LETTER: Review of Device Compassionate Use (HRP-574)

7 REFERENCES
7.1 21 CFR §50.23; 21 CFR §50.24; 21 CFR §56.102(d); 21 CFR §56.104(c).
7.2 21 CFR §812.36; 21 CFR §812.47.
1 PURPOSE
1.1 This procedure establishes the process for an IRB chair to designate IRB members who can conduct Non-Committee Reviews.
1.2 The process begins when the IRB chair instructs IRB staff (or the IRB staff confirms with the IRB chair) to designate an Experienced IRB Member to conduct Non-Committee Reviews.
1.3 The process ends when the IRB member has been noted in the IRB roster to conduct Non-Committee Reviews.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 IRB rosters are maintained using the “DATABASE: IRB Roster (HRP-601).”

4 RESPONSIBILITIES
4.1 IRB staff members carry out these procedures.

5 PROCEDURE
5.1 Obtain from (or confirm with) the IRB chair the name of the IRB member designated to conduct Non-Committee Reviews.
5.2 Verify that the IRB member is an Experienced IRB Member.

6 MATERIALS
6.1 DATABASE: IRB Roster (HRP-601)

7 REFERENCES
7.1 21 CFR §56.110(b).
7.2 45 CFR §46.110(b).
1 PURPOSE
1.1 This procedure establishes the process to prepare for a Non-Committee Review.
1.2 The process begins when an IRB staff member identifies an application as being possibly eligible for Non-Committee Review.
1.3 The process ends when the IRB staff member provides the materials to the Designated Reviewer.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 IRB rosters are maintained using HRP-601 - DATABASE - IRB Roster.
3.2 For individuals who are provided submitted materials, those individuals are expected to review the materials listed in the HRP-301 - WORKSHEET - Review Materials according to their role: “Documents Provided to All IRB Members and Alternate IRB Members,” “Additional Items Provided to Primary Reviewer,” and “Additional Items Provided to Scientific/Scholarly Reviewer.”

4 RESPONSIBILITIES
4.1 IRB staff members carry out these procedures.

5 PROCEDURE
5.1 Refer to HRP-601 - DATABASE - IRB Roster and select a Designated Reviewer.
5.1.1 If no Designated Reviewer is available, or if available Designated Reviewers are unable to perform a Non-Committee Review in a timely manner such that review by the convened IRB would result in a more timely review, schedule the protocol to be reviewed by the convened IRB.
5.2 For individuals who are provided materials to review, prepare the review materials using the HRP-301 - WORKSHEET - Review Materials and include all materials listed under the columns according to the individual’s role.
5.3 Add to the review materials:
5.3.1 HRP-402 - CHECKLIST - Non-Committee Review.
5.3.2 Any relevant minutes or correspondence.
5.4 Complete HRP-540 - LETTER - Designated Reviewer Materials (or similar correspondence) and send to the Designated Reviewer within five business days of receipt of a complete submission.

6 MATERIALS
6.1 HRP-301 - WORKSHEET - Review Materials
6.2 HRP-402 - CHECKLIST - Non-Committee Review
6.3 HRP-540 - LETTER - Designated Reviewer Materials
6.4 HRP-601 - DATABASE - IRB Roster

7 REFERENCES
7.1 21 CFR §56.110(b)
7.2 45 CFR §46.110(b)
1 PURPOSE

1.1 This procedure establishes the process for a Designated Reviewer to conduct a Non-Committee Review.
1.2 The process begins when the Designated Reviewer has the provided materials.
1.3 The process ends when the Designated Reviewer completes the review and returns the completed materials to an IRB staff member.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None.

3 POLICY

3.1 The Designated Reviewer may not disapprove research.
3.2 The Designated Reviewer utilizes all applicable worksheets in the review of research.
3.3 All applicable criteria for approval in HRP-314 - WORKSHEET - Criteria for Approval must be satisfied in order for the research to be approved using the expedited procedure.
3.4 All applicable criteria for approval in HRP-312 - WORKSHEET - Exemption Determination must be satisfied for research to be determined to be exempt (including applicable criteria for Limited IRB Review in HRP-319 - WORKSHEET - Limited IRB Review and Broad Consent when appropriate).

4 RESPONSIBILITIES

4.1 The Designated Reviewer carries out these procedures.

5 PROCEDURE

5.1 Review all materials.
5.2 Determine the required level of review. (Not Human Research, Human Research not Engaged, exempt Human Research (including exempt Human Research that requires Limited IRB Review), Human Research approved using the expedited procedure, or Human Research that requires review by a convened IRB).
5.3 If consultation is needed follow “SOP: Consultation (HRP-051).”
5.4 Complete the “CHECKLIST: Non-Committee Review (HRP-402).”
5.5 Return all materials and completed checklists to the IRB staff within 10 business days of receipt of materials.

6 MATERIALS

6.1 HRP-051 - SOP - Consultation
6.2 HRP-312 - WORKSHEET - Exemption Determination
6.3 HRP-314 - WORKSHEET - Criteria for Approval
6.4 HRP-319 - WORKSHEET - Limited IRB Review and Broad Consent
6.5 HRP-402 - CHECKLIST - Non-Committee Review

7 REFERENCES

7.1 21 CFR §56.110(b).
7.2 45 CFR §46.110(b).
1 PURPOSE

1.1 This procedure establishes the process to prepare for a convened IRB meeting.
1.2 The process begins when the agenda is closed, approximately 21 days before a meeting date.
1.3 The process ends when IRB meeting agenda materials have been sent or made available to IRB members.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None.

3 POLICY

3.1 At least one IRB member or consultant is responsible for scientific/scholarly review of research.
3.2 Protocols are reviewed by IRB members and consultants with sufficient expertise.
3.3 When IRB members review research that involves vulnerable subjects, at least one individual who is knowledgeable about or experienced in working with such subjects will be present at the meeting.
3.4 IRB members are provided sufficient information so that each member can provide an opinion on whether the regulatory criteria for approval are met.
3.5 Alternate IRB members serve the same function as other IRB members, except that if the alternate IRB member and the regular IRB member for whom the alternate member is substituting are both present only one member may vote.
3.6 Review materials are provided to all IRB members at least 7 days before convened meetings.

4 RESPONSIBILITIES

4.1 IRB staff members carry out these procedures.

5 PROCEDURE

5.1 Confirm which IRB members (regular, alternate, and chairs) will be present at the meeting.
5.2 Consult “DATABASE: IRB Roster (HRP-601)” to be aware of the experience, expertise, and representational capacity of the IRB.
5.3 Review all submissions placed on the agenda for a convened IRB meeting.
5.4 Prepare an agenda for the meeting.
   5.4.1 Assign a primary reviewer to each agenda item.
   5.4.2 Assign a scientific/scholarly reviewer to each agenda item who has scientific/scholarly expertise in the area of research. The primary reviewer and scientific/scholarly reviewer may be the same individual.
   5.4.3 If the scientific/scholarly reviewer is not an IRB member, determine whether the scientific/scholarly reviewer has a Conflicting Interest as defined in “SOP: Definitions (HRP-001).” If so, assign another scientific/scholarly reviewer.
5.5 Use “WORKSHEET: Quorum and Expertise (HRP-305)” to ensure that the meeting will be appropriately convened and to ensure the IRB will have the appropriate expertise for each protocol.
   5.5.1 If the meeting will not meet the quorum and expertise requirements, take steps to obtain the required attendance of members and consultants or cancel the meeting.
   5.5.2 Follow the procedures in “SOP: Consultation (HRP-051)” to obtain consultants. Note any consultants on the agenda.
5.6 For individuals who are provided materials (IRB members, scientific/scholarly reviewers, consultants):
   5.6.1 Prepare review materials using “WORKSHEET: Review Materials (HRP-301)” according to the individual’s role.
   5.6.2 Ensure review materials are available in the submission using “WORKSHEET: Review Materials (HRP-301).”
5.6.3 Deliver or mail review materials.

6 MATERIALS

6.1 DATABASE: IRB Roster (HRP-601)
6.2 SOP: Consultation (HRP-051)
6.3 SOP: Definitions (HRP-001)
6.4 WORKSHEET: Review Materials (HRP-301).
6.5 WORKSHEET: Quorum and Expertise (HRP-305).

7 REFERENCES

7.1 45 CFR §46.108(b)
7.2 21 CFR §56.108(b)
1 PURPOSE

1.1 This procedure establishes the process to conduct convened meetings.
1.2 The process begins when the IRB members gather for a convened meeting.
1.3 The process ends when the meeting is adjourned.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None.

3 POLICY

3.1 The IRB reviews research in accordance with the applicable regulatory criteria for approval.
3.2 The IRB chair (and vice chair, where applicable), votes as a regular member.
3.3 Meetings are conducted in person or via teleconference.
3.4 IRB attendance is captured by documenting in the IRB meeting minutes the IRB members and alternates in attendance, replacement of a voting member by an alternate, attendance of IRB members who participate through teleconference, and IRB members who are recused due to a conflicting interest.
3.5 If quorum is lost during a meeting, the IRB cannot take votes until the quorum is restored, even if more than half of the members are still present.
3.6 Substantive changes or requirements, requests for more information for IRB consideration, and other issues related to the criteria for approval require review and approval by the convened IRB.
3.7 Minor or prescriptive changes or requirements (modifications required to secure approval) may be reviewed for approval by the IRB chair or a designated individual.
3.8 The worksheets and checklists described in HRP-301 - WORKSHEET - Review Materials and listed below in “Section 6: MATERIALS” are provided to IRB members in advance of meetings per HRP-040 - SOP - IRB Meeting Preparation to conduct meetings and meet regulatory requirements.
3.9 For Veterans Administration (VA) Research “Substantive Changes” are defined as those ineligible for “Modifications Required to Secure Approval” as defined in this SOP.

4 RESPONSIBILITIES

4.1 The IRB chair carries out these procedures.
4.2 Primary reviewers lead IRB members through consideration of the regulatory criteria for approval.

5 PROCEDURE

5.1 Call the meeting to order.
5.2 Ask IRB members whether anyone has a Conflicting Interest in any item on the agenda and note the responses.
5.3 Ask IRB members if there are any questions about the report of completed non-committee reviews that was made available to the IRB prior to the meeting.
5.4 For each agenda item:
   5.4.1 Table the item when notified by IRB staff that requirements for review of a specific item as defined in HRP-305 - WORKSHEET - Quorum and Expertise are not met.  
   5.4.2 If there are IRB members with a Conflicting Interest, invite the IRB to ask questions of those members and then ask those members to leave for discussion and voting or if present by teleconference, be placed on hold or disconnect for discussion and voting.

---

1 “Tabled” is not an action of the IRB, but is a status based on the inability of the IRB to take an action because of reasons of quorum.
For each agenda item involving the initial review, modification or continuing review of a protocol:

5.5.1 If there is a consultant present, ask the consultant to present his or her review to the IRB.

5.5.2 If a consultant provided written information to the IRB, ask the primary reviewer to present that information to the IRB.

5.5.3 Ask the scientific or scholarly reviewer or primary reviewer to present the scientific or scholarly review to the IRB.

5.5.4 Ask the primary reviewer to lead the IRB through a discussion of the criteria in the HRP-314 - WORKSHEET - Criteria for Approval and all referenced checklists (listed below) to have the convened IRB determine which regulatory criteria are met (or continue to be met), which are not met (or no longer met), and which would be met if the investigator modified the protocol as requested by the IRB.

5.5.5 Restate the IRB’s consensus regarding any protocol specific findings justifying a determination when required by a checklist and not previously determined and documented.

5.5.6 Make a motion for one of the following actions:

5.5.6.1 Approve (with a specific continuing review interval for initial or continuing review, when applicable): Made when all criteria for approval are met. Include in motions for initial and continuing review the period of approval and the level of risk.

5.5.6.2 Modifications Required to Secure Approval (Conditional Approval) (with a specific continuing review interval for initial or continuing review, when applicable): Made when IRB members require specific modifications such that an IRB staff member can determine whether an investigator has made the required changes without judging whether a change meets the regulatory criteria for approval. When making this motion, the assigned primary reviewer restates the modifications required by the IRB members and the IRB member’s reasons for those changes.

5.5.6.3 Defer: Made when the research does not qualify for Approval or Modifications Required to Secure Approval and the IRB has recommendations that might make the protocol approvable. When making this motion, the assigned primary reviewer describes the IRB member’s reasons for the decision and describes recommendation to make the research approvable.

5.5.6.4 Disapprove: Made when the research does not qualify for Approval or Modifications Required to Secure Approval and the IRB has no recommendations that might make the protocol approvable. When making this motion, the assigned primary reviewer describes the IRB member’s reasons for the decision.

5.5.6.5 Suspension or Termination of IRB Approval: Made when current approved research does not qualify for Approval or Modifications Required to Secure Approval. When making this motion, have the primary reviewer use the HRP-321 - WORKSHEET - Review of Information Items to lead the convened IRB through a discussion of what actions are needed, if any, to protect subjects. The assigned primary reviewer describes the IRB member’s reasons for the decision.
5.5.7 Review any modifications required to secure approval to ensure that the IRB staff has recorded them.
   5.5.7.1 Ensure that the required modifications include all final contingencies on HRP-401 - CHECKLIST - Pre-Review.
   5.5.7.2 For a pending financial interest review indicate that a determination that the financial interest is not a conflict of interest or has been eliminated can be verified by the IRB staff, but if there is a management plan, it must return to the convened IRB for review.

5.6 For each agenda item that is new information (Unanticipated Problem Involving Risks to Subjects or Others, Serious Non-Compliance, Continuing Non-Compliance, Suspension of IRB Approval, or Terminations of IRB Approval):
   5.6.1 Have the primary reviewer use the HRP-321 - WORKSHEET - Review of Information Items to lead the convened IRB through a discussion of what actions are needed, if any, to protect subjects.
   5.6.2 Restate the IRB’s consensus regarding any actions that need to be taken to protect subjects.
   5.6.3 Make a motion for the IRB’s determination(s) regarding the action items (e.g., the motion is for the Principal Investigator to provide the IRB additional information regarding the status of currently enrolled subjects).
   5.6.4 Open the floor for additional discussion.
   5.6.4.1
   5.6.5 Call for a vote.
   5.6.5.1 Only IRB members may vote.
   5.6.5.2 If a member and an alternate are both present, only one may vote.
   5.6.5.3 Consultants may not vote.
   5.6.5.4 For a motion to be approved, it needs the approval of more than half of the members present at the meeting. (If there are 10 or 11 members present at the meeting, 6 votes are required for approval, which is greater than 5 and 5.5, respectively.)
   5.6.6 Re-invite IRB members with a Conflicting Interest back into the meeting.
   5.6.7 Provide any written information provided by a member or consultant to the IRB staff.

5.7 Adjourn the meeting when notified by IRB staff that quorum has been lost or when there is no further business.

6 MATERIALS
6.1 HRP-040 - SOP - IRB Meeting Preparation
6.2 HRP-301 - WORKSHEET - Review Materials
6.3 HRP-305 - WORKSHEET - Quorum and Expertise
6.4 HRP-308 - WORKSHEET - Pre-Review
6.5 HRP-314 - WORKSHEET - Criteria for Approval
6.6 HRP-315 - WORKSHEET – Advertisements
6.7 HRP-316 - WORKSHEET – Payments
6.8 HRP-317 - WORKSHEET - Short Form of Consent Documentation
6.9 HRP-318 - WORKSHEET - Additional Federal Agency Criteria
6.10 HRP-321 - WORKSHEET - Review of Information Items
6.11 HRP-323 - WORKSHEET - Criteria for Approval HUD
6.12 HRP-401 - CHECKLIST - Pre-Review
6.13 HRP-410 - CHECKLIST - Waiver or Alteration of Consent Process
6.14 HRP-411 - CHECKLIST - Waiver of Written Documentation of Consent
6.15 HRP-412 - CHECKLIST - Pregnant Women
6.16 HRP-413 - CHECKLIST - Non-Viable Neonates
6.17 HRP-414 - CHECKLIST - Neonates of Uncertain Viability
6.18 HRP-415 - CHECKLIST - Prisoners
6.19 HRP-416 - CHECKLIST - Children
6.20 HRP-417 - CHECKLIST - Cognitively Impaired Adults
6.21 HRP-418 - CHECKLIST - Non-Significant Risk Device
6.22 HRP-419 - CHECKLIST - Waiver of Consent Process for Emergency Research

7 REFERENCES

7.2 45 CFR §46.109, §46.116, §46.117.
1 PURPOSE
1.1 This procedure establishes the process to monitor quorum at convened IRB meetings.
1.2 The process begins when the IRB staff member responsible for monitoring quorum notifies the IRB chair that quorum has been attained.
1.3 The process ends when the meeting is adjourned.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None.

3 POLICY
3.1 None.

4 RESPONSIBILITIES
4.1 IRB staff members carry out these procedures.

5 PROCEDURE
5.1 At meetings consult the "WORKSHEET: Quorum and Expertise (HRP-305)" to determine that the meeting is appropriately convened by meeting the "QUORUM REQUIREMENTS" and notify the IRB chair when the meeting is appropriately convened.
5.2 Before each protocol consult the "WORKSHEET: Quorum and Expertise (HRP-305)" to determine that the meeting is appropriately convened by meeting the "EXPERTISE REQUIREMENTS" and notify the IRB chair when the meeting is not appropriately constituted for the review of that protocol.
5.3 When a member leaves the meeting room for any reason (including a Conflicting Interest) consult the "WORKSHEET: Quorum and Expertise (HRP-305)" to determine that the meeting continues to be appropriately convened by meeting the "QUORUM REQUIREMENTS" and notify the IRB chair when the meeting is not appropriately convened.

6 MATERIALS
6.1 WORKSHEET: Quorum and Expertise (HRP-305).

7 REFERENCES
7.1 45 CFR §46.108(b)
7.2 21 CFR §56.108(c)
1 PURPOSE
1.1 This procedure establishes the process to record minutes for convened meetings.
1.2 The process begins when the meeting is called to order.
1.3 The process ends when the minutes are finalized.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None.

3 POLICY
3.1 Minutes are to comply with regulatory and guidance requirements.
3.2 Minutes are to record separate deliberations for each action.
3.3 Minutes are officially approved on behalf of the IRB by the IRB chair or IRB manager.
3.4 IRB members may make corrections to minutes.
3.5 The IRB writes minutes and makes them available for review within 21 business days of the meeting date. Minutes are made available to the Institutional Official/Organizational Official (IO/OO).

4 RESPONSIBILITIES
4.1 IRB staff members carry out these procedures.

5 PROCEDURE
5.1 Use the HRP-501 - TEMPLATE MINUTES to record observations at meetings.
5.2 Under “Attendance Table” record each voting member (regular members and alternates) present at the meeting at any time: (Do not record non-voting members under “Attendance Table.”)
   5.2.1 Name.
   5.2.2 Status: E.g., chair, vice chair, scientific member, non-scientific member, unaffiliated member, prisoner representative.
   5.2.3 For alternate members who are substituting for a regular member, indicate the name of the regular member for whom the alternate member is substituting.
   5.2.4 Whether the member was present by teleconference.
5.3 Record the total number of members in HRP-601 - DATABASE - IRB Roster. Exclude alternate members in this count.
5.4 Record the number of members required for quorum. Divide the number of members by two and select the next whole number. For example, if there are 10 IRB members on the HRP-601 - DATABASE - IRB Roster, then 10/2 = 5 and the next whole number is 6. If there 11 IRB members on the HRP-601 - DATABASE - IRB Roster, then 11/2=5.5 and the next whole number is 6.
5.5 Indicate whether members present by teleconference received all pertinent material before the meeting and were able to actively and equally participate in all discussions. Delete if no members were present by teleconference.
5.6 Record the meeting start time.
5.7 Record a summary of each business item that was discussed.
5.8 For each protocol reviewed record:
   5.8.1 Type(s) of review: Initial review, continuing review, review of modifications to previously approved research, or review of Unanticipated Problem Involving Risks to Subjects or Others, Serious Non-Compliance, Continuing Non-Compliance, Suspension of IRB Approval, Termination of IRB Approval.
   5.8.2 Protocol Title
   5.8.3 Investigator name.
5.8.4 IRB identification number
5.8.5 Funding Agency, if any
5.8.6 Grant Title, if any
5.8.7 Grant ID, if any
5.8.8 IND or IDE, if any
5.8.9 Notes: Summarize issues useful to understand the agenda item. For example, a brief history of recent IRB actions
5.8.10 Consultant report: Summarize the key information provided by the consultant. Delete if there was no consultant.
5.8.11 Controverted issues and their resolution. Summarize the issues where IRB members expressed a difference of opinion. For each issue indicate the resolution or indicate that there was none. If no controverted issues, indicate "None."
5.8.12 Motion: Approved, Approved with Modifications (Conditional Approval), Deferred, Disapproved, Suspended, or Terminated. For initial or continuing review add the period of approval to the motion. If the protocol was tabled, indicate this.
5.8.13 Vote: Record as the number of members for, against, abstaining, absent, or recused. List the names of IRB members who were absent or recused. Do not count votes of consultants. If both a regular IRB member and the alternate IRB member are present at the meeting record the vote of just one.
  5.8.13.1 For: Voting for the motion.
  5.8.13.2 Against: Voting against the motion.
  5.8.13.3 Abstain: Present for the vote, but not voting “For” or “Against.”
  5.8.13.4 Absent: Listed under “Members Present” but not present for the discussion and vote on this protocol for reasons other than a Conflicting Interest. List the names of absent members in the vote. For example: “For: 7 Against: 3 Abstain: 2 Absent: 2 (Alice Baker, Charlie Delta) Recused: 0 Substitutions: 0”
  5.8.13.5 Recused: Listed under “Members Present” but not present for the discussion and vote on this protocol for because of a Conflicting Interest. List the names of recused members in the vote. For example: “For: 7 Against: 3 Abstain: 2 Absent: 0 Recused: 2 (Evelyn Foxtrot, George India) Substitutions: 0”
  5.8.13.6 Substitutions: Listed under “Members Present” When regular members and their alternate(s) are listed under “Members Present” and an alternate member substitutes for the regulator member, identify the name of the alternate to indicate which individual is serving as the voting member for this vote. May be deleted if there are no substitutions. For example: “For: 7 Against: 3 Abstain: 2 Absent: 0 Recused: 0 Substitutions: 1 (Evelyn Foxtrot substituted for George India)”
5.8.14 Level of risk determined by the convened IRB: Minimal Risk or greater than Minimal Risk.
5.8.15 Determinations and findings that require documentation: If the research involves waiver or alteration of consent, waiver of written documentation of consent, children, pregnant women, neonates, Prisoners, or cognitively impaired adults, include one or more of the “Determination/Protocol Specific Findings” tables in the HRP-501 - TEMPLATE MINUTES or enter that the determination is documented in IRB records and ensure that the corresponding completed checklist is in the IRB records. Otherwise delete.
5.8.16 Rationale for a significant/non-significant device determination: Describe the rationale for the determination. Otherwise delete.
5.8.17 Modifications required to secure approval: If this is the motion, complete the table with the required changes and corresponding reasons. Otherwise, delete.
5.8.18 Deferral/disapproval reasons and recommended changes: If this is the motion, complete the table with the recommendations and corresponding reasons. Otherwise, delete.

5.8.19 Suspension/termination reasons and recommended changes: If this is the motion, complete the table with the recommendations and corresponding reasons. Otherwise, delete.

5.8.20 Tabled reason: If the protocol was tabled, provide the reasons. Otherwise, delete.

5.9 Record the meeting end time.

5.10 Within 5 business days revise minutes for accuracy and provide them to the IRB chair or IRB manager for review and approval.

5.11 Once approved by the IRB chair or IRB manager, provide them to:

5.11.1 IO/OO or designee.

5.11.2 IRB members.

5.11.3 IRB members have 7 days to review the minutes. If no comments or revisions are received within 7 days, the minutes will be considered accepted.

5.12 Attach the following documents to the meeting agenda (or provide to IRB members if no meeting agenda):

5.12.1 List of protocols granted approval using the expedited procedure.

6 MATERIALS

6.1 HRP-501 - TEMPLATE MINUTES

7 REFERENCES

7.1 21 CFR §56.115(a)(2)

7.2 45 CFR §46.115(a)(2)
1 PURPOSE

1.1 This procedure establishes the process for the organization to review research that is not otherwise approvable, but because the research is not subject to regulatory approval no government agency will conduct a review of this research to determine whether it can be approved.

1.2 This process begins when the IRB determines that research involving children, pregnant women, or fetuses as subjects is not otherwise approvable, but presents a reasonable opportunity to understand, prevent, or alleviate a serious problem affecting those subjects health or welfare.

1.3 The process ends when the Institutional Official/Organizational Official (IO/OO) or designee communicates a decision to the IRB.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None.

3 POLICY

3.1 When research is not otherwise approvable, but because the research is not subject to regulatory approval no government agency will conduct a review of this research to determine whether it can be approved, this organization will conduct its own review that parallels the regulatory process.

3.2 The criteria used to make a determination are:

3.2.1 that the research in fact satisfies the conditions of IRB approvable research in “CHECKLIST: Non-Viable Neonates (HRP-413),” “CHECKLIST: Neonates of Uncertain Viability (HRP-414),” or “CHECKLIST: Children (HRP-416),” or “CHECKLIST: Pregnant Women (HRP-412)

3.2.2 All of the following criteria are met:

3.2.2.1 The research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children or pregnant women, fetuses or neonates.

3.2.2.2 The research will be conducted in accordance with sound ethical principles;

3.2.2.3 Adequate provisions are made for soliciting the assent of children, the permission of their parents or guardians, and the consent of subjects as required by "WORKSHEET: Criteria for Approval and Other Considerations (HRP-314)," "CHECKLIST: Non-Viable Neonates (HRP-413)," “CHECKLIST: Neonates of Uncertain Viability (HRP-414),” or “CHECKLIST: Children (HRP-416).”

4 RESPONSIBILITIES

4.1 The IO/OO or designee carries out these procedures.

5 PROCEDURE

5.1 Identify a panel of five or more experts in pertinent disciplines (e.g., science, medicine, education, ethics, and law) and relevant subject advocates to review the protocol.

5.2 Screen for Conflicting Interests of panel members and do not use panel members with a Conflicting Interest.

5.3 Inform potential experts that they will be asked to provide individual written recommendations and that their reports, as well as their identities, will be publicly available during the public review and comment period.

5.4 Publish in a form accessible to the public:
5.4.1 A request for written comments, including an Internet link to the protocol, relevant sections of grant applications, parental permission and assent documents, and relevant excerpts from the IRB minutes and correspondence.

5.4.2 The date and location of the expert panel meeting (to be held a minimum of 30 days after the notice is posted.)

5.4.3 Indicate that the panel meeting will be open to the public and that the public will be given an opportunity to comment at the panel meeting.

5.4.4 Note that written comments on posted materials must be submitted at least 7 days before the day of the panel meeting to be considered by the panelists (which will allow the public 21 days to comment on posted materials);

5.4.5 Indication that the panelists' reports/recommendations (see below) will be posted 14 days after the panel meets.

5.4.6 Invite comments for up to 30 days after the meeting of the convened panel for review and consideration by the panel.

5.5 Open the meeting to the public.

5.6 After the convened panel discussion occurs and public comments are received, have each panel member write an independent recommendation as to whether the protocol should proceed, proceed with modifications, or not proceed.

5.7 Post panel reports on the organization’s website for informational purposes for 30 days after the panel meeting.

5.8 Review the panel deliberations, reports, public comments, and make one of the following recommendations within 90 days of the convened panel meeting:

5.8.1 The organization approves support of the research as submitted;

5.8.2 The organization approves support of the research, but with required and/or recommended modifications; or

5.8.3 The organization disapproves support of the research.

5.9 Inform the IRB and the investigator.

5.10 Post the decision on the organization’s Website.

6 MATERIALS

6.1 CHECKLIST: Pregnant Women (HRP-412)

6.2 CHECKLIST: Non-Viable Neonates (HRP-413)

6.3 CHECKLIST: Neonates of Uncertain Viability (HRP-414)

6.4 CHECKLIST: Children (HRP-416)

6.5 WORKSHEET: Criteria for Approval and Other Considerations (HRP-314)

7 REFERENCES

7.1 45 CFR §46.207, 45 CFR §46.407

7.2 21 CFR §50.24(e), 21 CFR §50.54(b), 21 CFR §812.66
1 PURPOSE
1.1 This procedure establishes the process to identify and manage Conflicting Interest of IRB members.
1.2 The process begins when an IRB member is asked to review an IRB submission.
1.3 The process ends when an IRB member has either identified a Conflicting Interest and notified IRB staff, or when an IRB member has determined that he or she does not have a Conflicting Interest.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 IRB members are responsible to know the definition of Conflicting Interest and self-identify when they have a Conflicting Interest.

4 RESPONSIBILITIES
4.1 IRB members (regular and alternate) follow these procedures.

5 PROCEDURE
5.1 Before reviewing research, IRB members are to determine whether they have a Conflicting Interest with research.
5.2 If an IRB member has a Conflicting Interest for review outside a meeting (e.g., the expedited procedure), he or she is to notify the IRB staff and return all materials.
5.3 If an IRB member has a Conflicting Interest for review of a submission for which he or she has been assigned as a primary or scientific reviewer, he or she is to notify the IRB staff so the submission can be re-assigned.
5.4 If an IRB member has a Conflicting Interest for review of research at a meeting, he or she is to notify the meeting chair, stay in the meeting room only to answer questions about the research, and to leave the meeting room for discussion and voting regarding that research.

6 MATERIALS
6.1 None

7 REFERENCES
7.1 21 CFR §56.107(e).
7.2 45 CFR §46.107(e).
1 PURPOSE
1.1 This procedure establishes the process for the IRB to obtain consultants.
1.2 The process begins when the IRB staff or IRB member has identified the need for consultation.
1.3 The process ends when the consultant has provided additional expertise to the IRB.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 The IRB invites consultants with competence in special areas to assist in the review of issues which require expertise beyond or in addition to that available on the IRB.
3.2 Consultants with a Conflicting Interest may not provide information to the IRB.

4 RESPONSIBILITIES
4.1 For review by a convened IRB, IRB staff members carry out these procedures.
4.2 For Non-Committee Review, the Designated Reviewer carries out these procedures.

5 PROCEDURE
5.1 Identify a consultant with the required expertise who can provide a review. Identify individuals as follows:
   5.1.1 IRB members from other committees
   5.1.2 Other employees of the organization
   5.1.3 External consultants
5.2 Contact the consultant and determine availability for review.
5.3 Determine whether the consultant has a Conflicting Interest as defined in "SOP: Definitions (HRP-001)." If so, obtain another consultant.
5.4 Use "WORKSHEET: Review Materials (HRP-301)" to determine which documents to make available to the consultant so the IRB can obtain the additional expertise needed, and make these documents available to the consultant. If the additional expertise needed does not require review of any materials, no materials need be provided.
5.5 For review by the convened IRB:
   5.5.1 Make the consultant's written comments, if any, available to the IRB members attending the meeting.
   5.5.2 If the consultant did not provide a written report or if requested by an IRB member, invite the consultant to the IRB meeting.
5.6 For Non-Committee Review:
   5.6.1 Directly obtain the information (oral or written) from the consultant.
   5.6.2 Document information received with the name of the consultant.

6 MATERIALS
6.1 SOP: Definitions (HRP-001)
6.2 WORKSHEET: Review Materials (HRP-301)

7 REFERENCES
7.1 21 CFR §56.107(f)
7.2 45 CFR §46.107(f)
1 PURPOSE
1.1 This procedure establishes the process for communications after a protocol is reviewed.
1.2 The process begins when:
   1.2.1 A Designated Reviewer has completed a Non-Committee Review and provided completed materials to the IRB staff; OR
   1.2.2 An IRB meeting has adjourned and the IRB chair or IRB manager has approved the minutes; OR
   1.2.3 An IRB staff member has verified that modifications required to secure approval have been made.
1.3 The process ends when all correspondence related to IRB determinations and actions have been sent and additional tasks have been completed.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 The IRB reports its findings and actions to the investigator.
3.2 The IRB reports its findings and actions to the institution.
3.3 When the IRB disapproves research, it provides the investigator with a statement of the reasons for the decision and gives the investigator an opportunity to respond in person or in writing.
3.4 Communication of review results to investigators are to be completed within 10 business days of the IRB meeting or receipt of the completed Non-Committee Review materials.
3.5 Reporting of Serious Non-Compliance; Continuing Non-Compliance; Suspension of IRB Approval; Termination of IRB Approval; and Unanticipated Problem Involving Risks to Subjects or Others to outside agencies is to take place within 30 days from the recognition of a reportable problem.
   3.5.1 For Veterans Affairs (VA) research that involves:
       3.5.1.1 An Unanticipated Problem Involving Risks to Subjects or Others that is a local research death, notification to the VA facility Director, the Research Compliance Officer (RCO) and the Associate Chief of Staff/R&D must occur within 5 business days of the convened IRB’s determination(s).
       3.5.1.2 Information determined by the IRB to constitute an Unanticipated Problem Involving Risks to Subjects or Others, Serious Non-Compliance or Continuing Non-Compliance, notification to the VA facility Director, the Research Compliance Officer (RCO) and the Associate Chief of Staff/R&D must occur within 5 business days of the convened IRB’s determination(s).
       3.5.1.2.1 If the IRB is unable to make a determination on the apparent Unanticipated Problem Involving Risks to Subjects or Others within 30 calendar days of the convened IRB’s initial review due to insufficient information or due to a lack of sufficient time to complete its review, the IRB must notify the VA medical facility Director, the Research Compliance Officer (RCO), and the ACOS/R&D in writing no later than five (5) business days after the determination was due.

4 RESPONSIBILITIES
4.1 IRB staff members carry out these procedures.

5 PROCEDURE
5.1 If the Non-Committee Review indicated a Conflicting Interest or a lack of expertise, follow HRP-031 - SOP - Non-Committee Review Preparation.
5.2 If the title, principal investigator, or research staff for a protocol changed, update the list of protocols.

5.3 For initial reviews, continuing reviews or modifications:
   5.3.1 Refer to HRP-302 - WORKSHEET - Approval Intervals to calculate approval intervals (if applicable).
   5.3.2 For approvals requiring continuing review, set a deadline for receipt of the continuing review application 30 days before study expiration.
   5.3.3 Refer to HRP-303 - WORKSHEET - Communication of Review Results and send all applicable letters within 30 business days.
   5.3.3.1 Send the letter to the inside addresses and cc list as directed by the letter.
   5.3.4 For continuing reviews or modifications to studies where enrollment is suspended and the submission does not change the enrollment suspension status, document in the study record that enrollment to the study remains suspended.

5.4 For determinations of Serious Non-Compliance; Continuing Non-Compliance; Suspension of IRB Approval; Termination of IRB Approval; or Unanticipated Problem Involving Risks to Subjects or Others:
   5.4.1 Refer to HRP-303 - WORKSHEET - Communication of Review Results and send all applicable letters to the Principal Investigator within 5 business days.
   5.4.1.1 Send the letter to the inside addresses and cc list as directed by the letter.
   5.4.2 Use HRP-520 - LETTER - External Report NOT Including OHRP or HRP-526 - External Report to DOD to send to outside agencies within 30 business days from the determination of a reportable problem.

5.5 If reporting to an external agency is required:
   5.5.1 When sending to DHHS only, complete the OHRP Incident Report Online Form.¹
   5.5.2 Use HRP-520 - LETTER - External Report NOT Including OHRP, HRP-520a – LETTER – External Report OHRP and Other Agencies, or HRP-526 - External Report to DOD to send to outside agencies within 30 business days from the determination of a reportable problem.
   5.5.2.1 If reporting to both DHHS and any other outside agency concurrently, utilize the OHRP Incident Report Form and HRP-520a.
   5.5.2.2 If reporting to other outside agencies NOT including DHHS, complete HRP-520 - LETTER - External Report NOT Including OHRP or HRP-526 - External Report to DOD as appropriate.

6 MATERIALS
   6.1 HRP-031 - SOP - Non-Committee Review Preparation
   6.2 HRP-302 - WORKSHEET - Approval Intervals
   6.3 HRP-303 - WORKSHEET - Communication of Review Results
   6.4 HRP-520 - LETTER - External Report NOT Including OHRP
   6.5 HRP-520a – LETTER – External Report OHRP and Other Agencies
   6.6 HRP-526 - External Report to DOD

7 REFERENCES
   7.2 21 CFR §56.108(a)(1), 21 CFR §50.24(e), 21 CFR §50.54(b), 21 CFR §812.66
   7.3 VHA Directive 1058.01 October 22, 2020

¹ See: https://www.hhs.gov/ohrp/compliance-and-reporting/guidance-on-reporting-incident/index.html
1 PURPOSE

1.1 This procedure establishes the process to identify institutional financial interests that may cause an institutional conflict of interests.

1.2 The process begins when the Organizational Official/Institutional Official (IO/OO) or designee is informed of a change in the institution’s financial holdings outside of standard investments.

1.3 The process ends when the IRB staff are provided an updated list of the institution’s financial holdings.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 An institutional financial conflict of interests exists when any of the following might affect the design, conduct, or reporting of research:

3.1.1 Licensing, technology transfer, patents
3.1.2 Investments of the organization
3.1.3 Gifts to the organization when the donor has an interest in the research
3.1.4 Financial interests of senior administrative officials
3.1.5 Other financial interests

3.2 Senior administrative officials are required to disclose their financial interests to the Conflict of Interests Officer:

3.2.1 Upon joining the organization
3.2.2 Every year
3.2.3 When there are changes to financial interests

3.3 The Technology Transfer Office, Grants and Contracts Office, legal counsel, and the Conflict of Interests Officer are to notify the IO/OO or designee of any change in the institution’s financial holdings not controlled by the institution’s investment managers related to:

3.3.1 Licensing (e.g., licensing or technology transfer agreements)
3.3.2 Investments of the organization
3.3.3 Gifts to the organization when the donor has an interest in the research
3.3.4 Financial interests of senior administrative officials
3.3.5 Other financial interests

3.4 The fiduciary responsibility of the institution’s investment managers is to maintain a diversified portfolio of holdings that meets the institution’s goals in terms of capital appreciation, income, and risk. Institutional officials may not influence the decisions of the institution’s investment managers. This institution considers such investments to be similar to diversified mutual funds and not subject to disclosure under this policy.

3.5 The evaluation and management of an institutional conflict of interest may not vary by funding or regulatory oversight.

3.6 If an institutional financial holding related to prospective or ongoing Human Research is identified, it will be managed according to “SOP: Financial Conflicts of Interests (HRP-055)”.

4 RESPONSIBILITIES

4.1 The IO/OO or designee carries out these responsibilities.

5 PROCEDURE

5.1 Upon receipt of information of a change in financial interest update the list of investments that are not controlled by the institution’s investment managers. Include information about the name of the company, the names of related companies, and affected products or services.

5.2 Provide a copy of the updated list to the IRB staff.
6 MATERIALS

6.1 SOP: Financial Conflicts of Interests (HRP-055)

7 REFERENCES

7.1 None
1 PURPOSE

1.1 This procedure establishes the process to evaluate a report of an individual financial interest of an investigator or research staff Related to the Research or an institutional financial interest Related to the Research.

1.2 The process begins when ORSP determines that an investigator or research staff has reported a financial interest Related to the Research or the IRB staff have detected an institution financial interest Related to the Research.

1.3 The process ends when the Chief Research Officer (CRO) has evaluated the reported interest and communicated the results of this evaluation to the IRB.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 The Vice Provost for Research serves as the Chief Research Officer.

3.2 For any or all steps of this procedure, the CRO may have the Conflicts of Interests Committee follow the procedure whenever the CRO believes that institutional consensus is needed to make a decision.

3.3 Individuals are considered to have an institutional responsibility and are subject to this policy when they are involved in any of the following:

3.3.1 The design, conduct, or reporting of research

3.3.2 Research consultation

3.3.3 Teaching

3.3.4 Professional practice

3.3.5 Institutional committee memberships

3.3.6 Service on panels such as Institutional Review Boards or Data and Safety Monitoring Boards

3.4 Individuals subject to this policy are required to complete financial conflicts of interest training initially, at least every four years, and immediately when:

3.4.1 Joining the organization

3.4.2 Financial conflicts policies are revised in a manner that changes investigator requirements

3.4.3 Non-compliant with financial conflicts policies and procedures

3.5 Individuals subject to this policy are required to disclose their institutional responsibility to conduct research and the financial interests Related to the Research:

3.5.1 On submission of an initial review.

3.5.2 At least annually on submission of continuing review.

3.5.3 Within 30 days of discovering or acquiring (e.g., through purchase, marriage, or inheritance) a new financial interest

3.6 Travel disclosures are to include the purpose of the trip, the identity of the sponsor or organizer, the destination, and the duration.

3.7 The document "UNIVERSITY OF MASSACHUSETTS POLICY FOR PROMOTING OBJECTIVITY IN BIOMEDICAL RESEARCH":

3.7.1 Describes when individuals are considered to have an institutional responsibility

3.7.2 Describes when individuals subject to this policy are required to complete financial conflicts of interest training

3.7.3 Defines "Significant Financial Interest"

3.8 The financial disclosure threshold for Human Research may vary by funding or regulatory oversight.

3.9 Violations of this policy or proscribed management plans can lead to:
3.9.1 Loss or restriction of privileges to conduct research
3.9.2 Other employment actions as allowed by Human Resources Policies and Procedures.

3.10 Records related to disclosures and management of financial conflicts of interest are to be retained for at least three years from completion of the research.

3.11 For Veterans Administration (VA) research:
3.11.1 Veterans Administration (VA) facilities are not required to follow PHS requirements, even when research is funded by a PHS agency (e.g., NIH).
3.11.2 When serving as the IRB of record for a VA facility, the VA financial conflict of interest form must be used, and the form may not be created, re-drafted, or changed.

4 RESPONSIBILITIES
4.1 The Vice Provost for Research carries out these procedures or ensures that a committee follows these procedures.

5 PROCEDURE
5.1 Ensure committee members do not participate in the review of any conflict of interests in which the member has Conflicting Interest.
5.2 Review the reported financial interest and the research protocol.
5.2.1 If the financial interest and research protocol has already been reviewed, and if needed, managed, notify the IRB staff of this determination in writing and stop processing subsequent steps of this procedure.
5.3 Determine whether the reported financial interest is related to the research.
5.3.1 If the financial interest is not related to the research, notify the IRB staff of this determination in writing and stop processing subsequent steps of this procedure.
5.4 Determine whether the reported financial interest could directly and significantly affect the design, conduct, or reporting (i.e., the reported financial interest is a conflict of interests) of the Human Research.
5.4.1 If there is no conflict of interests, notify the IRB staff of this determination in writing and stop processing subsequent steps of this procedure.
5.5 If a conflict of interest exists, determine under what circumstances, if any, should a conflicted individual (in the case of individual financial interest) or the organization (in case of institutional financial interest) be allowed to participate in:
5.5.1 Subject recruitment.
5.5.2 Prescreening for inclusion/exclusion criteria.
5.5.3 The consent process.
5.5.4 The clinical treatment of subjects, separate from the research interventions or procedures.
5.5.5 Clinical evaluation of subjects during the research, separate from the research interventions or procedures, including adverse event evaluation and reporting.
5.6 Create a written management plan, considering the following options:
5.6.1 Public disclosure of the financial interests.
5.6.2 Disclosure of the financial interests to subjects.
5.6.3 Appointment of an independent monitor capable of taking measures to protect the design, conduct, and reporting of the research against bias resulting from the financial conflict of interest.
5.6.4 Change of personnel or personnel responsibilities, or disqualification of personnel from participation in all or a portion of the research.
5.6.5 Reduction or elimination of the financial interest (e.g., sale of an equity interest).
5.6.6 Severance of relationships that create financial conflicts.
5.6.7 Modification of the research plan.
5.6.8 Involvement of external individuals in key portions of the protocol.
5.6.9  Use of an external IRB.
5.6.10 A retrospective review.
5.6.11 A mitigation report.
5.6.12 A plan to monitor and enforce the implementation of the management plan.

5.7 Provide the written management plan to the involved individual or office for comment and review.
5.8 Finalize the written management plan.
5.9 Provide the IRB staff of the reviewing IRB with the written management plan so the IRB can make the final decision as to whether the financial interest and its management, if any, allows the research to be approved.
5.10 When required provide the final determination to the funding or regulatory agencies.
5.11 Maintain a copy of determinations and management plans in the records.

6 MATERIALS
6.1 None

7 REFERENCES
7.1 42 CFR §50
7.2 45 CFR §94
1 PURPOSE

1.1 This procedure establishes the process to manage allegations of undue influence of the HRPP.

1.1.1 Undue influence with regards to the HRPP refers to any attempt to interfere with the review process of the IRB or to inappropriately place pressure on an IRB member, IRB Chair, or IRB staff in order to obtain a specific outcome from the IRB or one of its members or staff.

1.2 This procedure begins when the Institutional Official/Organizational Official (IO/OO) or designee (e.g., Assistant Director of ORSP Research Compliance and Integrity, IRB Chair, IRB Manager) learns of an allegation of undue influence of the HRPP.

1.3 This procedure ends when any undue influence of the HRPP has been mitigated.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 The Institution grants the IRB the authority:

3.1.1 To approve, require modifications to secure approval, or disapprove all human research activities overseen and conducted by the Institution.

3.1.2 To suspend or terminate approval of human research not being conducted in accordance with the IRB’s requirements or that has been associated with unexpected serious harm to participants.

3.1.3 To observe, or have a third party observe, the consent process.

3.1.4 To observe, or have a third party observe, the conduct of the research.

3.2 Officials of the Institution are not allowed to approve the human research if it has not been approved by the IRB.

3.3 The IRB separates business functions from ethical review. Individuals responsible for business development may not serve as IRB members, may not be involved in daily operations of the review process, and may not discuss business development with IRB members.

3.4 Individuals in the Institution may not

3.4.1 Attempt to influence the review of human research through real or perceived action on any performance review, promotion or tenure decision of any IRB member, IRB staff or any individual involved in the conduct or review of human research.

3.4.2 Communicate the Institution’s financial issues regarding specific protocols to individuals responsible for the review process.

3.4.3 Answer questions about the Institution’s business issues posed by individuals responsible for the review process where the answers might unduly influence or appear to unduly influence the review process determinations made as part of the criteria for approval.

3.5 All individuals in the Institution are responsible for reporting allegations of undue influence of the HRPP or review process to the IO/OO or designee within 5 days of becoming aware of the allegation.

4 RESPONSIBILITIES

4.1 The IO/OO or designee carries out these procedures.

5 PROCEDURE
5.1 Gather information to determine the veracity of the report using discretion regarding the most efficient and effective methods. Methods to gather information can include, but are not limited to:
  5.1.1 Interviews of individuals inside and outside the Institution
  5.1.2 Review of records inside and outside the Institution
  5.1.3 Consultation with internal or external entities
5.2 If the report has no basis in fact, take no further action under this SOP.
5.3 Take appropriate steps to eliminate the undue influence using discretion regarding the most efficient and effective methods. Steps may include, but are not limited to:
  5.3.1 No action
  5.3.2 Verbal counseling
  5.3.3 Education
  5.3.4 Reassignment of Duties
  5.3.5 Termination of Employment
5.4 Document the findings and actions, if any, related to undue influence of the HRPP.

6 MATERIALS
  6.1 None

7 REFERENCES
  7.1 21 CFR §56.109(a), §56.109(f), §56.112, §56.113
  7.2 45 CFR §46.109(a), §46.109(e), §46.112, §46.113
SOP: Annual HRPP Evaluations of the HRPP

1 PURPOSE
1.1 This procedure establishes the process to conduct annual evaluations of the human research protection program.
1.2 The process begins the first business day of each June.
1.3 The process ends when all evaluations have been completed and communicated to those evaluated.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 The human research protection program is evaluated annually.
3.2 The subject outreach program for enhancing the understanding of subjects, prospective subjects, and communities is accomplished by making the document HRP-104 - BROCHURE - Should I Take Part in Research available to the patient population.

4 RESPONSIBILITIES
4.1 IRB staff ensure completion of these procedures.

5 PROCEDURE
5.1 Have the Institutional Official/Organizational Official or designee evaluate the following resources provided to the human research protection program and make adjustments as part of the budgeting process.
   5.1.1 Space
   5.1.2 HRPP educational program
   5.1.3 Legal counsel
   5.1.4 Conflicts of interests
   5.1.5 Quality improvement plan
5.2 Have the Institutional Official/Organizational Official (IO/OO) or designee evaluate the HRPP’s emergency preparedness plan and make changes when appropriate.
   5.2.1 When updates to the HRPP emergency preparedness plan are made, the IRB Director will designate appropriate IRB staff to make changes to associated educational materials for the HRPP research community.
5.3 Evaluate whether the number of IRBs is appropriate to the volume and types of research reviewed.
   5.3.1 Provide a copy of the evaluation to the IO/OO or designee.
   5.3.2 If the number of IRBs is not appropriate to the volume and types of research reviewed, work with the IO/OO or designee to modify the IRB structure.
5.4 Have the IO/OO or designee evaluate the knowledge, skills, and performance of each IRB chair using HRP-326 - WORKSHEET - Performance Evaluation for IRB Chairs.
   5.4.1 Communicate the results of the evaluation to each IRB chair and the IO/OO or designee.
   5.4.2 If needed, work with each IRB chair to develop a plan to improve the individual’s knowledge, skills, and performance.
5.5 Have the IRB chair or IRB manager evaluate the knowledge, skills, and performance of each regular and alternate IRB member using HRP-327 - WORKSHEET - Performance Evaluation for IRB Members.
   5.5.1 IRB members will be evaluated one year after an IRB member has been appointed to a committee and two years after that.
5.5.2 Have the IRB Chair or IRB Manager utilize HRP-327 - WORKSHEET - Performance Evaluation for IRB Members to complete the evaluation. Communicate the results of the evaluation to each IRB member and the IO/OO or designee.

5.5.3 Provide a copy of the evaluation to the IO/OO or designee.

5.5.4 Provide each IRB member with a copy of his or her evaluation.

5.5.5 If needed, work with each IRB member to develop a plan to improve the individual’s knowledge, skills, and performance.

5.6 Have the IO/OO or designee utilize HRP-326 - WORKSHEET - Annual Performance Evaluation Criteria for IRB Chairs to complete the evaluation.

Follow the Human Resources annual employee evaluation process to evaluate the knowledge, skills, and performance of IRB staff. HRP-328 - WORKSHEET - Performance Evaluation for IRB Staff may be used as part of the evaluation.

5.6.1 Document the results of this evaluation as part of the annual employee evaluation process.

5.6.2 Provide each IRB staff with a copy of his or her evaluation.

5.6.3 If needed, work with each IRB staff person to develop a plan to improve the individual’s knowledge, skills, and performance.

5.7 Use the HRP-304 - WORKSHEET - IRB Composition to evaluate whether the composition of the IRB meets regulatory and organizational requirements.

5.7.1 Provide a copy of the evaluation to the IO/OO or designee.

5.7.2 If the composition of an IRB does not meet regulatory and organizational requirements, work with the IO/OO or designee to modify the IRB composition.

5.8 Evaluate the subject outreach plan.

5.8.1 Consider the following areas when evaluating the outreach plan:

5.8.1.1 Whether the existing scope and content of HRPP outreach materials continue to be adequate;

5.8.1.2 Whether modifications to existing outreach materials are necessary;

5.8.1.3 Whether or not the HRPP’s existing materials are being regularly utilized by the IRB Office or by members of the research community in their own interaction with the communities in which they conduct research;

5.8.1.4 Whether there are new opportunities to provide outreach activities to the community, and;

5.8.1.5 Whether additional information is needed from the research community to assess the extent to which outreach materials are used and outreach activities take place.

5.8.2 Provide a copy of the evaluation to the IO/OO or designee.

5.8.3 If the subject outreach program is not meeting organizational goals, work with the IO/OO or designee to modify the plan. Modifications may include, but are not limited to:

5.8.3.1 Modifying existing outreach materials;

5.8.3.2 Developing new materials;

5.8.3.3 Surveying the research community to identify and participate in additional outreach opportunities, and;

5.8.3.4 Working directly with community organizations to identify and participate in additional outreach opportunities.

5.9 Check whether each member of a Veterans Administration (VA) IRB or Veterans Administration (VA) representative has been a member longer than 2 years, and if so, send the member HRP-560 - LETTER - IRB Appointment.
5.10 Review HRP-080 - SOP - IRB Formation and Registration to determine if IRB registration requires updating.¹

5.11 Check when the last time the federalwide assurance (FWA) was updated or renewed. If more than 2 years, update/renew the federalwide assurance (FWA).²

6 MATERIALS

6.1 HRP-080 - SOP - IRB Formation and Registration
6.2 HRP-104 - BROCHURE - Should I Take Part in Research
6.3 HRP-304 - WORKSHEET - IRB Composition
6.4 HRP-326 - WORKSHEET - Performance Evaluation for IRB Chairs
6.5 HRP-327 - WORKSHEET - Performance Evaluation for IRB Members
6.6 HRP-328 - WORKSHEET - Performance Evaluation Criteria for IRB Staff
6.7 HRP-560 - LETTER - IRB Appointment
6.8 HRP-562 - LETTER - IRB Appreciation

7 REFERENCES


---


1 PURPOSE
1.1 This procedure establishes the process to conduct quality improvement of the human research protection program.
1.2 The process begins the first business day of each month.
1.3 The process ends when all evaluations have been completed and if needed, acted upon.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 The goal of the quality improvement plan is to achieve and maintain compliance and to achieving targeted levels of quality, efficiency, and effectiveness of the HRPP.
3.2 Objectives of the quality improvement program are to:
   3.2.1 Improve compliance of investigators with their responsibilities.
   3.2.2 Improve compliance of minutes with regulatory compliance.
   3.2.3 Increase efficiency of recording and finalizing minutes.
3.3 The measures of the quality improvement program are defined in:
   3.3.1 CHECKLIST: Investigator Quality Improvement Assessment (HRP-430)
   3.3.2 CHECKLIST: Minutes Quality Improvement Assessment (HRP-431)

4 RESPONSIBILITIES
4.1 IRB staff ensure completion of these procedures.

5 PROCEDURE
5.1 Conduct Investigator QI Assessment:
   5.1.1 Based upon the request of the IRB or upon selection of the Organizational Official / Institutional Official (IO/OO) or Director of the Office of Research and Sponsored Programs, complete "TEMPLATE LETTER: Investigator Quality Improvement Assessment (HRP-534)" and Send "CHECKLIST: Investigator Quality Improvement Assessment (HRP-430)" for selected investigator(s).
5.2 Review the results of “CHECKLIST: Investigator Quality Improvement Assessment (HRP-430)” sent out the previous month, track the results, and examine for significant trends.
5.3 Conduct HRPP Quality Improvement Assessment:
5.4 Review the results of all Investigator QI Assessments sent out the previous quarter and examine for significant trends.
5.5 Complete "CHECKLIST: Minutes Quality Improvement Assessment (HRP-431)" on the minutes of the previous month. Track compliance and the days required to complete minutes and examine for significant trends.
5.6 Send the results to the IRB manager and Organizational Official / Institutional Official (IO/OO) or designee.
   5.6.1 If the results of any evaluations demonstrate inconsistency, recurring noncompliance or misinterpretation of HRPP requirements, high variability, or are outside performance targets, work with the IRB manager and IO/OO to implement an intervention.
   5.6.2 Interventions may include policy and procedure modifications, education and training efforts, system modifications, or other corrective actions.

6 MATERIALS
6.1 CHECKLIST: Investigator Quality Improvement Assessment (HRP-430)
6.2 CHECKLIST: Minutes Quality Improvement Assessment (HRP-431)
6.3 TEMPLATE LETTER: Investigator Quality Improvement Assessment (HRP-534)
### SOP: Monthly HRPP Evaluations

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>DATE</th>
<th>AUTHOR</th>
<th>APPROVED BY</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRP-061</td>
<td>11/30/18</td>
<td>M. Williams</td>
<td>M. Meyer</td>
<td>2 of 2</td>
</tr>
</tbody>
</table>

## 7 REFERENCES

### 7.1 None
1 PURPOSE
1.1 This procedure establishes the process to complete daily tasks required to monitor the research review process.
1.2 The process begins each day.
1.3 The process ends when the tasks have been completed.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 The IRB Plus system checks the database for protocols whose continuing review progress report is due in 30 business days and sends “TEMPLATE LETTER: Continuing Review Reminder (HRP-530)”
3.2 The IRB Plus system checks the database for protocols that have expired due to lack of continuing review and sends the “TEMPLATE LETTER: Expiration of IRB Approval (HRP-533).”

4 RESPONSIBILITIES
4.1 IRB staff members are responsible for carrying out this procedure.

5 PROCEDURE
5.1 If the IRB Plus system finds individuals whose training has lapsed:
   5.1.1 Consider placing the principal investigator on the Restricted list.
5.2 If the IRB Plus system finds protocols that have expired due to lack of continuing review:
   5.2.1 Follow “SOP: Expiration of IRB Approval (HRP-063)”
5.3 Check for protocols that do not require continuing review:
   5.3.1 Complete and send the “TEMPLATE LETTER: Annual Reminder (HRP-535)”

6 MATERIALS
6.1 SOP: New Information (HRP-024)
6.2 SOP: Expiration of IRB Approval (HRP-063)
6.3 SOP: IRB Membership Removal (HRP-083)
6.4 TEMPLATE LETTER: Continuing Review Reminder (HRP-530)
6.5 TEMPLATE LETTER: Expiration of IRB Approval (HRP-533)
6.6 TEMPLATE LETTER: Annual Reminder (HRP-535)
6.7 TEMPLATE LETTER: Training Reminder (HRP-531)
6.8 TEMPLATE LETTER: Failure to Undergo Training (HRP-554)
6.9 TEMPLATE LETTER: Failure to Submit Continuing Review (HRP-550)

7 REFERENCES
7.1 None
**SOP: Expiration of IRB Approval**

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>DATE</th>
<th>AUTHOR</th>
<th>APPROVED BY</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRP-063</td>
<td>12/20/2019</td>
<td>M. Williams</td>
<td>M. Meyer</td>
<td>1 of 1</td>
</tr>
</tbody>
</table>

1 **PURPOSE**

1.1 This procedure establishes the process for a Designated Reviewer to determine whether current subjects may continue in expired research.

1.2 The process begins when the Designated Reviewer is notified of a request by an investigator of a request for current subjects to continue in expired research.

1.3 The process ends when the Designated Reviewer has communicated a decision and documented the decision in writing.

2 **REVISIONS FROM PREVIOUS VERSION**

2.1 None.

3 **POLICY**

3.1 If research is granted “Modifications Required to Secure Approval” and expires before responsive materials are reviewed and approved, these procedures are to be followed.

4 **RESPONSIBILITIES**

4.1 A Designated Reviewer is responsible to follow these procedures.

5 **PROCEDURE**

5.1 Determine from the investigator which subjects need to continue in the expired research, what procedures are being requested to continue, and why.

5.2 Do not allow new subjects to be enrolled under any circumstances.

5.3 Determine which subjects can continue in the research based on these principles:

   5.3.1 In general, research procedures should be safely discontinued.

   5.3.2 In general, the only research procedures that should continue are those that are not available outside of the research context. If the required procedures can be provided as standard of care, these should be provided as such.

   5.3.3 In general, research procedures conducted to collect data with no direct benefit to the subject should not continue.

   5.3.4 In some cases, an ethical issue may be raised where the above general principles may not be followed.

5.4 In the case of Veterans Administration (VA) research, have the IRB chair determine within 2 business days whether participants may continue participating in the research interventions or interactions.

5.5 Communicate with the investigator using HRP-532 - LETTER - Conti Subj Expired Research.

6 **MATERIALS**

6.1 HRP-532 - LETTER - Conti Subj Expired Research

7 **REFERENCES**

7.1 None
1 PURPOSE

1.1 This procedure establishes the process to certify approval for investigator submission of large-scale human genomic data to an NIH-designated data repository.

1.2 The process begins when an investigator contacts IRB staff for certification of the genomic data sharing plan.

1.3 The process ends when the Institutional Official/Organizational Official (IO/OO) has certified and communicated to the investigator.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None.

3 POLICY

3.1 Investigators must request certification from IRB staff prior to investigator submission of large-scale human genomic data or approval of funding.

4 RESPONSIBILITIES

4.1 The IRB Director or designee verifies for the IO/OO that all data meet criteria for submission to the data repository.

5 PROCEDURE

5.1 Use HRP-332 - WORKSHEET - NIH GDS Institutional Certification to evaluate and document whether the investigator's genomic data sharing plan meets the criteria for submission to an NIH-designated data repository.

5.2 Populate the applicable NIH Extramural Institutional Certification form. Pass the letter to the IO/OO for review and certification.

5.2.1 Provide NIH Provisional Institutional Certification when required by investigators prior to IRB review of the data sharing plan.

5.3 Save a copy of the signed form in IRB Office records.

5.4 Communicate certification approval to the investigator and provide a copy of the signed GDS Institutional Certification form for the investigator to forward to the NIH.

6 MATERIALS

6.1 HRP-332 - WORKSHEET - NIH GDS Institutional Certification

7 REFERENCES


7.2 NIH Points to Consider for IRBs and Institutions in their Review of Data Submission Plans for Institutional Certifications Under NIH's Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies (GWAS) (https://osp.od.nih.gov/wp-content/uploads/PTC_for_IRBs_and_Institutions.pdf)

7.3 NIH Institutional Certification Forms (https://osp.od.nih.gov/scientific-sharing/institutional-certifications/)

1 PURPOSE

1.1 This SOP establishes the process for initiating a response to an emergency/disaster situation impacting the HRPP or HRPP operations. Challenges to HRPP operations or the conduct of Human Research may arise, for example, from:

1.1.1 Extreme weather events.
1.1.2 Natural disasters.
1.1.3 Man-made disasters.
1.1.4 Infectious disease outbreaks.

1.2 The process starts when an emergency/disaster situation impacting the HRPP has occurred, or in preparation for scenarios where a potential emergency situation is imminent (e.g., natural disaster, man-made disaster, infectious disease pandemic, etc.) and HRPP operations and/or the ability of investigators to conduct Human Research is, or is likely to be, adversely impacted.

1.3 The process ends when the impact to the HRPP and the conduct of Human Research is assessed, and appropriate guidance is provided to HRPP personnel and the broader Human Research community.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 HRPP leadership defers to designated institutional leadership and institution-wide disaster and emergency response planning and limits HRPP-specific disaster and emergency response planning only to those areas of operations or human research protections not otherwise covered by institution-level plans.

3.2 The HRPP evaluates its emergency response plans at least annually in accordance with the HRP-101 - Human Research Protection Program Plan and HRP-060 - SOP - Annual Evaluations of the HRPP.

4 RESPONSIBILITIES

4.1 The IRB Director or designee is responsible for carrying out these procedures

5 PROCEDURE

5.1 If an emergency/disaster has occurred, or there is an imminent possibility of an upcoming emergency/disaster, assess the nature of the event and the appropriate response.

5.1.1 Consult HRP-101 - Human Research Protection Program Plan to reference existing HRPP specific or institution specific emergency preparedness plans or information already in place.

5.1.2 Contact the IO/OC and or designated institutional personnel responsible for institutional level emergency preparedness, and determine whether there are new or revised institution level emergency preparedness plans relevant to the current or anticipated emergency.

5.1.2.1 If yes, proceed in accordance with those plans and determine whether further contact or notification of the human research community is necessary.

5.2 Assess whether the emergency/disaster could impact HRPP operations:
5.2.1 If the current or anticipated emergency/disaster will prevent any upcoming IRB meetings from properly convening in-person, and an in-person meeting was planned, determine whether the meeting can be conducted virtually or via teleconference.

5.2.1.1 If yes, work with IRB members and staff to arrange for a virtual meeting. Follow HRP-040 - SOP - IRB Meeting Preparation to confirm quorum and availability of IRB members.

5.2.1.2 If a virtual meeting is also not feasible under the circumstances caused by the emergency/disaster, determine whether to cancel or reschedule the meeting(s).

5.2.1.3 If currently approved Human Research has or will expire prior to IRB review due to the IRB meeting cancelation/rescheduling, follow HRP-063 - SOP - Expiration of IRB Approval.

5.2.2 If IRB staff will be unable to complete their protocol processing and review responsibilities during the emergency/disaster, or if capacity will be limited for a period of time:

5.2.2.1 Work with the staff to use any available capacity to prioritize protocol processing, pre-review, and review of continuing review submissions.

5.2.2.2 If currently approved Human Research has or will expire prior to IRB review due to IRB office capacity limitations follow HRP-063 - SOP - Expiration of IRB Approval.

5.2.2.3 Work with the IO/OO to notify the research community of the IRB Office’s limited capacity to process and review submissions.

5.2.2.4 When the emergency/disaster no longer presents a limitation to IRB Office functions, work with the IO/OO to notify the IRB members and staff and research community that normal business operations have resumed.

5.2.3 If impact to local HRPP operations will be extensive or long-lasting, determine whether reliance on an external IRB(s) is required.

5.2.3.1 If reliance on one or more external IRBs is required and the necessary reliance agreements are not currently in place, work with the IO/OO to identify appropriate candidates for external IRB reliance and follow HRP-801 - SOP - Establishing Authorization Agreements.

5.2.4 If data or records (paper or electronic) are unavailable during the current or anticipated emergency/disaster, consult with local IT support and or electronic system vendors to implement alternative procedures to access data/backup data.

5.3 Assess whether the emergency/disaster could necessitate additional flexibility in IRB review processes. If yes:

5.3.1 Review HRP-352 - WORKSHEET - Additional Emergency-Disaster Review Considerations with the IRB Chair(s) and staff in advance of upcoming IRB meetings.

5.3.2 Communicate to IRB Members (including Designated Reviewers performing non-committee reviews) that the additional considerations in the worksheet may be incorporated into IRB reviews where appropriate to maximize regulatory flexibility while continuing to assure research subject safety during the emergency/disaster.

5.3.3 Determine whether additional communications to the research community are necessary to inform investigators of any additional measures the IRB will take to maximize regulatory flexibility during the emergency/disaster and notify the community as appropriate.

5.4 Assess whether the emergency/disaster could impact some or all investigators’ ability to conduct Human Research. If yes:
SOP: Response Plan for Emergencies-Disasters
Impacting the HRPP

5.4.1 Notify the research community of the need for protocol-specific emergency/disaster risk mitigation planning. Use HRP-542 - LETTER - Implementation of HRPP Emergency-Disaster Response Plan.

5.4.2 Provide investigators with copies of (or links to) HRP-108 - FLOWCHART - Study-Specific Emergency-Disaster Risk Mitigation Planning.

5.4.3 Provide investigators with copies of (or links to) HRP-351 - WORKSHEET - Protocol-Specific Emergency-Disaster Risk Mitigation Planning.

5.4.4 If the emergency/disaster could impact clinical care standards which could in turn impact research, develop guidance for researchers that clarify what does and does not require IRB review (e.g., screening procedures mandated by the health care system in which a clinical trial is being conducted).

5.4.5 When the emergency/disaster no longer presents a limitation to Human Research activities, work with the IO/OO to notify the research community that normal business operations have resumed.

5.5 Evaluate whether the nature of the emergency/disaster may pose additional threats or risk to specific aspects of the institution's research activities or facilities. (For example, man-made disasters, industrial accidents, or terrorist threats could potentially impact some chemical, biological, or radiologic facilities to a greater extent than other facilities.)

5.5.1 If yes, and if broader institution-level emergency/disaster preparedness measures do not already address these specific activities or facilities, work with the IO/OO and appropriate institutional leadership to escalate and address any additional threats or risks.

6 MATERIALS

6.1 HRP-060 - SOP - Annual Evaluations of the HRPP
6.2 HRP-101 - HUMAN RESEARCH PROTECTION PROGRAM PLAN
6.3 HRP-108 - FLOWCHART - Study-Specific Emergency-Disaster Risk Mitigation Planning
6.4 HRP-351 - WORKSHEET - Protocol-Specific Emergency-Disaster Risk Mitigation Planning
6.5 HRP-352 - WORKSHEET - Additional Emergency-Disaster Review
6.6 HRP-542 - LETTER - Implementation of HRPP Emergency-Disaster Response Plan
6.7 HRP-801 - SOP - Establishing Authorization Agreements

7 REFERENCES

7.1 AAHRPP Element I.1.H
1 PURPOSE

1.1 This procedure establishes the process to maintain IRB records.
1.2 The process begins when records are received or created.
1.3 The process ends when records have been filed.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 IRB records are to include:
   3.1.1 Protocol files.
   3.1.2 Minutes of IRB meetings.
   3.1.3 Copies of all correspondence between the IRB and the investigators.
   3.1.4 Current and all previous IRB member rosters.
   3.1.5 Current and all previous IRB member files.
   3.1.6 Current and all previous policies and procedures.

3.2 Protocol files are to include, as applicable:
   3.2.1 All submitted materials.
   3.2.2 Protocols.
   3.2.3 Investigator brochures.
   3.2.4 Scientific evaluations.
   3.2.5 Recruitment materials.
   3.2.6 Consent documents.
   3.2.7 DHHS-approved sample consent document and protocol, when they exist.
   3.2.8 Progress reports submitted by investigators.
   3.2.9 Reports of injuries to subjects.
   3.2.10 Records of continuing review activities, including the rationale for requiring continuing review of research that otherwise would not require continuing review when applicable under the 2018 Rule.
   3.2.11 Data and safety monitoring board reports.
   3.2.12 Amendments.
   3.2.13 Reports of unanticipated problems involving risks to subjects or others.
   3.2.14 Documentation of non-compliance.
   3.2.15 Correspondence between the IRB and investigator related to the protocol.
   3.2.16 Significant new findings and statements about them provided to subjects.
   3.2.17 For initial and continuing review of research by the expedited procedure:
      3.2.17.1 The specific permissible category.
      3.2.17.2 Description of action taken by the reviewer.
      3.2.17.3 Any findings required under the regulations.
      3.2.17.4 The rationale for a determination that research that otherwise meets a category for expedited review is greater than Minimal Risk.
   3.2.18 For exemption determinations the specific category of exemption.
   3.2.19 Unless documented in the IRB minutes determinations required by the regulations and protocol-specific findings supporting those determinations for:
      3.2.19.1 Waiver or alteration of the consent process.
      3.2.19.2 Research involving pregnant women, fetuses, and neonates.
      3.2.19.3 Research involving Prisoners.
      3.2.19.4 Research involving children.
      3.2.19.5 Research involving adults unable to consent.
3.2.19.6 Significant/non-significant device determinations.

3.2.20 For each protocol’s initial and continuing review, the frequency for the next continuing review, including the rationale for requiring continuing review for protocols approved by expedited review that otherwise would not require continuing review.

3.2.21 The institution will maintain record of all research conducted by the organization reviewed by an external IRB. Records will include all materials identified in section 3.2

3.2.22 For Veterans Administration (VA) research:
3.2.22.1 Correspondence between the IRB and the Veterans Administration (VA) Research and Development Committee.
3.2.22.2 Internal or local serious adverse events.
3.2.22.3 Documentation of protocol deviations.
3.2.22.4 Reports of complaints from subjects
3.2.22.5 Records of expedited review activities
3.2.22.6 HIPAA Authorization documents
3.2.22.7 Audit results and documentation of compliance with remediation requirements

3.3 Protocol files are maintained in chronological order with the latest information in front.
3.4 Policies and procedures include:
3.4.1 Checklists.
3.4.2 Forms.
3.4.3 SOPs.
3.4.4 Template letters.
3.4.5 Template minutes.
3.4.6 Worksheets.

3.5 IRB member files include a resume for each IRB member.

4 RESPONSIBILITIES
4.1 IRB staff members are responsible to carry out these procedures.

5 PROCEDURE
5.1 Minutes of IRB meetings: File in minutes folder.
5.2 File correspondence related to a specific protocol in the protocol file.
5.3 File correspondence NOT related to a specific protocol in a file related to that person or topic.
5.4 IRB member rosters: File in IRB member roster folder.
5.5 IRB membership records (e.g., curricula vita and resumes): File in IRB member files.
5.6 Policies and procedures:
5.6.1 File current policies and procedures in policies and procedures folder.
5.6.2 File replaced policies and procedures in the policies and procedures history file.

6 MATERIALS
6.1 None

7 REFERENCES
7.1 None
1 PURPOSE

1.1 This procedure establishes the process to create and update standard operating procedures and associated checklists and worksheets.

1.2 The process begins when the IRB manager or Institutional Official / Organizational Official (IO/OO) or designee determines that a standard operating procedure needs to be created or modified.

1.3 The process ends when the new or revised standard operating procedure has been approved and filed.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 None

4 RESPONSIBILITIES

4.1 The IRB manager carries out these procedures.

5 PROCEDURE

5.1 For a new standard operating procedure, assign a number.

5.2 Assign an author and approver.

5.3 Have the author create or update the standard operating procedure following the “TEMPLATE SOP (HRP-505)” or update the associated checklist or worksheet.

5.4 Have the approver review and approve the document.

5.5 Once approved by the approver:

5.5.1 Update the approval/effective date.

5.5.2 File and maintain the approved new or revised document in the standard operating procedure files.

5.5.3 Post the approved procedure on the Human Research Protection Program Web site.

5.5.4 File and retain the previous version, in the standard operating procedure files.

5.5.5 Send an email to affected individuals informing them of the change.

6 MATERIALS

6.1 TEMPLATE SOP (HRP-505)

7 REFERENCES

7.1 None
1 PURPOSE
1.1 This procedure establishes the process to retain IRB records.
1.2 The process begins each year in June.
1.3 The process ends when records that no longer need to be retained are destroyed.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 Protocol files are to be retained as long as required by law and then destroyed.
3.2 All records not in protocol files are retained indefinitely.
3.3 Records may be maintained in printed form or electronically.
3.4 Protocols in which there was no subject enrollment or no research was conducted are to be retained the same as protocols where research was conducted.
3.5 All records for research conducted or funded by a Common Rule department or agency are to be accessible for inspection and copying by authorized representatives of that agency at reasonable times and in a reasonable manner.
3.6 Records maintained that document compliance or non-compliance with Department of Defense (DOD) regulations shall be made accessible for inspection and copying by representatives of the DOD at reasonable times and in a reasonable manner as determined by the supporting DOD component.
3.7 All records for research subject to FDA regulations are to be accessible for inspection and copying by authorized representatives of FDA at reasonable times and in a reasonable manner.
3.8 All records are to be accessible for inspection and copying by the Veterans Administration (VA) Research and Development Committee at reasonable times and in a reasonable manner.
3.9 Veterans Administration (VA) IRB records are retained in accordance with VHA’s Records Control Schedule.

4 RESPONSIBILITIES
4.1 IRB staff members carry out these procedures.

5 PROCEDURE
5.1 Destroy protocol files for Veterans Administration (VA) research per Records Control Schedule 10-1 (VHA RCS 10-1).
5.2 Destroy protocol files for the Department of Defense (DOD) research when approved by the Department of Defense. The agency may require submitting records to the Department of Defense for archiving.
5.3 Destroy all other protocol files when the protocol has been closed, withdrawn, or terminated more than three years unless otherwise required by law.
5.3.1 Study files relating to exempt research are retained for at least three years after the last IRB action or after withdrawal by the submitter.
5.3.2 Study files for non-exempt research are retained for at least three years after disapproval by the IRB or lapse of IRB approval.
5.3.3 Study files relating to research activities submitted with an application to the IRB and declared to be not Human Research by the IRB are retained for at least three years.
5.3.4 Study files designated by legal counsel as being on “legal hold” are not to be destroyed until the legal hold is removed.
5.3.5 In the case of multi-center research, three years is referenced to the organization’s involvement in the research, not the entire study.
5.4 After the period of record retention, all paper-based IRB-related documents will be destroyed by shredding. Information technology will be notified to securely destroy any electronic documents. A record of the date of destruction of the study file with study title and IRB ID will be documented.

6 MATERIALS
   6.1 None

7 REFERENCES
   7.1 VHA Directive 1200.05 dated January 7, 2019
1 PURPOSE

1.1 This procedure establishes the process to form a new IRB or update the OHRP IRB registration of an existing IRB.

1.2 The process begins when the Institutional Official / Organizational Official (IO/OO) or designee determines the need for a new IRB or updated OHRP IRB registration.

1.3 The process ends when the IRB is registered, the federalwide assurance (FWA) is updated (if needed), and all members have completed training (if needed).

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 IRB rosters are maintained using the “DATABASE: IRB Roster (HRP-601).”

3.2 IRB registrations on file with OHRP will be made or updated as follows:

3.2.1 To register any additional IRB before it is designated under an FWA and reviews research conducted or supported by HHS.

3.2.2 Within 90 days after changes regarding the contact person who provided the IRB registration information or the IRB chairperson,

3.2.3 Within 30 days of the change if an FDA-regulated IRB decides to review additional types of FDA-regulated products (e.g., to review device studies if it only reviewed drug studies previously) or to discontinue reviewing clinical investigations regulated by FDA.

3.3 A revised FWA Addendum will be submitted to the Veterans Administration (VA) for any modifications to a FWA (other than telephone, address, or email changes).

3.4 A membership roster for all IRB(s) to be designated on a VA medical facility’s FWA must be submitted to ORO FWA staff at the time of the IRB’s designation as an IRB of Record on the FWA.

4 RESPONSIBILITIES

4.1 IRB staff members carry out these procedures.

4.2 The IO/OO or designee appoints IRB members, alternate members, IRB chairs, and if used, other officers (e.g., vice chairs.)

5 PROCEDURE

5.1 Determine from the IO/OO or designee whether the IRB will conduct all reviews without limitation or will be limited to certain types of reviews. Indicate this on the “IRB Scope” tab of the “DATABASE: IRB Roster (HRP-601).”

5.1.1 For internal IRBs:

5.1.1.1 Select:

5.1.1.1.1 At least five individuals to serve as IRB members.

5.1.1.1.2 Additional individuals to serve as alternate IRB members, if needed.

5.1.1.1.3 At least one of the individuals to be the IRB chair.

5.1.1.2 Follow “SOP: IRB Member Addition” for each IRB member.

5.1.1.3 Use “WORKSHEET: IRB Composition (HRP-304)” and revise the selected individuals as needed to ensure that the IRB is appropriately constituted.

5.1.1.4 Notify the IRB manager when all individuals have completed training.

5.2 Register the new IRB, or update an existing IRB’s OHRP registration as required by this policy, by following the instructions available at the OHRP website: https://www.hhs.gov/ohrp/register-irbs-and-obtain-fwas/irb-registration/new-irb-registration/index.html
5.3 Submit a new/revised FWA and VA FWA Addendum to ORO FWA staff who will submit the FWA to HHS-OHRP (through ORO FWA staff).

6 MATERIALS

6.1 HRP-082 - SOP - IRB Membership Addition
6.2 HRP-202 - FORM - IRB Member Information
6.3 HRP-304 - WORKSHEET - IRB Composition
6.4 HRP-560 - LETTER - IRB Appointment
6.5 HRP-601 - DATABASE - IRB Roster

7 REFERENCES

7.1 45 CFR §46.103, 45 CFR §46.107, 45 CFR §46.108, 45 CFR §46.115(a)(5).
7.2 21 CFR §56.107, 21 CFR §56.115(a)(5).
7.3 VHA Directive 1058.03 September 17, 2020
7.4 AAHRPP elements I.1.A, II.1.A-C
1 PURPOSE

1.1 This procedure establishes the process to remove an IRB.
1.2 The process begins when the Institutional Official/Organizational Official (IO/OO) or designee determines that an IRB is no longer needed.
1.3 The process ends when the IRB is unregistered with OHRP and the federalwide assurance (FWA) is updated.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 IRB rosters are maintained using the “DATABASE: IRB Roster (HRP-601).”

4 RESPONSIBILITIES

4.1 IRB staff members carry out these procedures.

5 PROCEDURE

5.1 For internal IRBs:

5.1.1 For each IRB member who will no longer serve as an IRB member prepare a “TEMPLATE LETTER: IRB Member Thank You (HRP-561),” have them signed by the IO/OO or designee, and send to the former IRB members.
5.1.2 Unregister the IRB with OHRP.
5.1.3 Remove the IRB from the federalwide assurance (FWA).
5.1.4 Remove members from “DATABASE: IRB Roster (HRP-601).”
5.1.5 File:

5.1.5.1 DATABASE: IRB Roster (HRP-601)
5.1.5.2 Federalwide assurance (FWA)
5.1.5.3 TEMPLATE LETTER: IRB Member Thank You (HRP-561)

5.2 For external IRBs follow the requirements of the inter-institutional agreement or contract.

6 MATERIALS

6.1 DATABASE: IRB Roster (HRP-601)
6.2 TEMPLATE LETTER: IRB Member Thank You (HRP-561)

7 REFERENCES

7.1 45 CFR §46.107, 45 CFR §46.103(b)(3), 45 CFR §46.115(a)(5).
7.2 21 CFR §56.107, 21 CFR §56.115(a)(5).

---

SOP: IRB Membership Addition

1 PURPOSE
1.1 This procedure establishes the process to appoint and re-appoint an IRB member.
1.2 The process begins when an individual expresses interest, is nominated or applies to join the IRB in consultation with the IRB manager, Institutional Official/ Organizational Official (IO/OO) or designee. (This may be a completely new IRB member, or re-appointment of a previous member.)
1.3 The process ends when the IRB roster is updated and the new member has completed training.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 IRB rosters are maintained using the HRP-601 - DATABASE - IRB Roster.
3.2 Changes in IRB membership will be promptly reported to the Veterans Administration (VA) medical facility.¹

4 RESPONSIBILITIES
4.1 IRB staff members carry out these procedures.
4.2 The IO/OO or designee appoints IRB members, alternate members, IRB chairs, and if used, other officers (e.g., vice chairs).

5 PROCEDURE
5.1 Have the individual complete the HRP-202 - FORM - IRB Member Information.
5.2 Obtain a copy of the individual’s résumé or curriculum vita.
5.3 Use the information in the completed HRP-202 - FORM - IRB Member Information and the individual’s résumé or curriculum vita to determine if the individual qualifies as a scientist or nonscientist, and if they are affiliated or unaffiliated.
5.4 Interview the individual to assess suitability and availability.
5.4.1 Determine from the IO/OO or designee whether the individual will be a regular IRB member, alternate IRB member, or IRB chair.
5.4.2 In any instance for which the scientific or non-scientific status or affiliation status of a newly appointed or re-appointed IRB member may be questionable, the IO/OO or designee will be consulted before proceeding with the appointment.
5.4.3 For Veterans Administration (VA) representatives, communicate with the Veterans Administration (VA) Medical Center Director in writing to obtain confirmation of the appointment.
5.5 Schedule a time for the applicant to attend and observe an IRB meeting, as applicable.
5.6 Add the individual to the HRP-601 - DATABASE - IRB Roster.
5.7 Complete HRP-304 - WORKSHEET - IRB Composition and revise the membership as needed to ensure that the IRB is appropriately constituted.
5.8 Prepare a HRP-560 - LETTER - IRB Appointment for the individual.
5.9 Provide to the IO/OO or designee for review and approval:
5.9.1 HRP-202 - FORM - IRB Member Information.
5.9.2 Résumé or curriculum vita.
5.9.3 Completed HRP-560 - LETTER - IRB Appointment.
5.10 If not approved, select another individual and restart at 5.1.
5.11 Once the appointment letter is signed:

¹ Also see VHA Handbook 1058.03.
5.11.1 Send the signed HRP-560 - LETTER - IRB Appointment to the individual.
5.11.2 If the individual requires training, schedule the individual for training.
5.11.3 Update the registration of all affected IRBs.²

5.12 File:
5.12.1 HRP-601 - DATABASE - IRB Roster
5.12.2 Signed IRB appointment/re-appointment letter
5.12.3 HRP-202 - FORM - IRB Member Information.
5.12.4 Résumé or curriculum vita.
5.12.5 Any other signed agreements.

5.13 Notify the IRB manager when the individual has completed training.
5.14 Add the individual’s “Committee Member” role in the system.

5.14.1 If applicable, update the “Update Eligible Designated Reviewers” activity.

6 MATERIALS
6.1 HRP-202 - FORM - IRB Member Information
6.2 HRP-304 - WORKSHEET - IRB Composition
6.3 HRP-560 - LETTER - IRB Appointment
6.4 HRP-561 - LETTER - IRB Thank You
6.5 HRP-601 - DATABASE - IRB Roster

7 REFERENCES
7.1 45 CFR §46.107, 45 CFR §46.108(a)(2), 45 CFR §46.115(a)(5).
7.2 21 CFR §56.107, 21 CFR §56.115(a)(5).
7.3 VHA Directive 1200.05 January 7, 2019
7.4 AAHRPP elements I.1.E, II.1.A-C

SOP: IRB Membership Removal

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>DATE</th>
<th>AUTHOR</th>
<th>APPROVED BY</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRP-083</td>
<td>12/10/2021</td>
<td>M. Williams</td>
<td>M. Meyer</td>
<td>1 of 1</td>
</tr>
</tbody>
</table>

1 PURPOSE

1.1 This procedure establishes the process to remove an IRB member.
1.2 The process begins when an IRB member resigns or is removed from one or more IRBs. This procedure applies if an individual is a member of more than one IRB and is being removed from some but not all IRBs.
1.3 The process ends when the IRB registration is updated.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 The Institutional Official/Organizational Official (IO/OO) or designee may remove IRB members, alternate members, IRB chairs, and if used, other officers (e.g., vice chairs) with consultation from the IRB manager and IRB chair(s).
3.2 IRB rosters are maintained using HRP-601 - DATABASE - IRB Roster.

4 RESPONSIBILITIES

4.1 IRB staff members carry out these procedures.

5 PROCEDURE

5.1 Remove the individual from “DATABASE: IRB Roster (HRP-601).”
5.2 Complete “WORKSHEET: IRB Composition (HRP-304)” to ensure that the IRB is appropriately constituted.
   5.2.1 If not, identify one or more replacement members and follow “SOP: IRB Member Addition (HRP-082).”
5.3 Prepare a “TEMPLATE LETTER: IRB Member Thank You (HRP-561),” have it signed by the IO/OO or designee, and send to the individual.
5.4 Update the registration of all affected IRBs.¹
5.5 File:
   5.5.1 DATABASE: IRB Roster (HRP-601)
   5.5.2 TEMPLATE LETTER: IRB Member Thank You (HRP-561)
5.6 Remove individual’s “Committee Member” role in the system.
   5.6.1 If applicable, update the “Update Eligible Designated Reviewers” activity.

6 MATERIALS

6.1 HRP-082 - SOP - IRB Membership Addition
6.2 HRP-304 - WORKSHEET - IRB Composition
6.3 HRP-561 - LETTER - IRB Thank You
6.4 HRP-601 - DATABASE - IRB Roster

7 REFERENCES

7.1 45 CFR §46.107, 45 CFR §46.103(b)(3), 45 CFR §46.115(a)(5)
7.2 21 CFR §56.107, 21 CFR §56.115(a)(5)
7.3 AAHRPP elements II.1.A, II.1.C

SOP: IRB Meeting Scheduling and Notification

1 PURPOSE
1.1 This procedure establishes the process to schedule and notify individuals of convened meetings.
1.2 The process begins when there are approximately fewer than 180 days of meetings on the current schedule.
1.3 The process ends when meetings are scheduled at least six months in advance and individuals in the organization are notified of the schedule.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 Whenever possible the IRB schedules meetings at least 90 days in advance.
3.2 Scheduled meetings are to occur at intervals appropriate for the quantity, complexity, and frequency of required actions, and to permit adequate oversight of the progress of approved research.
3.3 Additional meetings may be scheduled on an ad hoc basis.

4 RESPONSIBILITIES
4.1 The IRB manager carries out these procedures.

5 PROCEDURE
5.1 Create a schedule of meetings for each IRB.
5.2 Post the schedule on the organization’s Web site.
5.3 Notify the following individuals of the updated schedule with an email providing a link to the IRB Web page with the schedule information:
   5.3.1 IRB members.
   5.3.2 Investigators and research staff on the IRB email list.
   5.3.3 Institutional Official/Organizational Official (IO/OO) or designee.

6 MATERIALS
6.1 None

7 REFERENCES
7.1 ICH-GCP E6 3.3.2
1 PURPOSE

1.1 This procedure establishes the process to obtain informed consent from subjects, the Legally Authorized Representatives (LAR) of adults unable to consent, or the parents or guardians of children.

1.2 The process begins when an individual identifies a subject as a potential candidate for a research study.

1.3 The process ends when a subject or the subject’s LAR provides legally effective informed consent or declines to do so.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 In this procedure “investigator” means a principal investigator or an individual authorized by the principal investigator and approved by the IRB to obtain consent for the specific protocol, such as a co-investigator, research assistant, or coordinator.

3.2 In this procedure “subject/representative” means:

3.2.1 The subject when the subject is an adult capable of providing consent.

3.2.2 LAR when the subject is an adult unable to give consent.

3.2.3 One or both biologic or adoptive parents when the subject is a child or in the absence of a parent a person other than a parent authorized under applicable law to consent on behalf of the child to general medical care.

3.3 If the subject/representative understands more than one language, whenever possible, conduct the consent process in the preferred language of the subject/representative.

3.4 If the subject is an adult unable to consent:

3.4.1 The IRB must have specifically approved the protocol to allow the enrollment of adults unable to consent.

3.4.2 Permission is obtained from a LAR.

3.4.3 A LAR must be in the class or persons approved by institutional policy or the IRB. See “SOP: Legally Authorized Representatives, Children, and Guardians (HRP-013).”

3.5 If the subject is a child:

3.5.1 The IRB must have specifically approved the protocol to allow the enrollment of children.

3.5.2 Permission is obtained from both parents unless:

3.5.2.1 One parent is deceased, unknown, incompetent, not reasonably available;

3.5.2.2 Only one parent has legal responsibility for the care and custody of the child; or

3.5.2.3 The IRB has specifically approved the protocol to allow the permission of one parent regardless of the status of a second parent.

3.5.3 In the absence of a parent permission may be obtained from an individual authorized to consent under applicable law on behalf of a child to general medical care.

3.6 If the subject/representative cannot speak English:

3.6.1 The IRB must have specifically approved the protocol to allow the enrollment of subjects able to speak language that the subject understands.

3.7 Conduct all discussions in a private and quiet setting.

3.8 Any knowledgeable individual may:

3.8.1 Review the study with subject/representative to determine preliminary interest.

3.8.2 If the subject/representative is interested, notify an investigator.

3.8.3 If the subject/representative is not interested, take no further steps regarding recruitment or enrollment.
4 RESPONSIBILITIES

4.1 The principal investigator is responsible to ensure these procedures are carried out.

5 PROCEDURE

5.1 If the consent process will be documented in writing with the long form of consent documentation:
   5.1.1 Obtain the current IRB approved consent form.
   5.1.2 Verify that you are using the most current IRB-approved version of the study specific consent form and that the consent form is in language understandable to the subject/representative.
   5.1.3 Provide a copy of the consent form to the subject/representative. Whenever possible provide the consent form to the subject/representative in advance of the consent discussion.
   5.1.4 If the subject/representative cannot read obtain an impartial witness to be present during the entire consent discussion to attest that the information in the consent form and any other information provided was accurately explained to, and apparently understood by, the subject/representative, and that consent was freely given. The witness may be a family member or friend. The witness may not be a person involved in the design, conduct, or reporting of the research study.
   5.1.5 If the subject/representative cannot speak English, obtain the services of an interpreter fluent in both English and the language understood by the subject/representative. The interpreter may be a member of the research team, a family member, or friend of the subject/representative.
   5.1.6 Read the consent document (or have an interpreter read the translated consent document) with the subject/representative. Begin with a concise and focused presentation of key information that is most likely to assist the subject/representative to understand the reasons why one might or might not want to participate in the research. Explain the details in such a way that the subject/representative understands what it would be like to take part in the research study.

5.2 If the consent process will be documented in writing with the short form of consent documentation:
   5.2.1 Obtain the current IRB approved short consent form and summary (same as the English consent form used for long form of consent documentation).
   5.2.2 Verify that you are using the most current IRB-approved version of the study specific short consent form and summary that the short consent form is in language understandable to the subject/representative.
   5.2.3 Provide copies to the subject/representative. Whenever possible provide the short consent form and summary to the subject/representative in advance of the consent discussion.
   5.2.4 Obtain the services of an interpreter fluent in both English and the language understood by the subject/representative. The interpreter may be a member of the research team, family member, or friend of the subject/representative.
   5.2.5 Obtain the services of an impartial witness who is fluent in both English and the language spoken by the subject/representative to be present during the entire consent discussion to attest that the information in the short consent form, summary, and any other information provided was accurately explained to, and apparently understood by, the subject/representative, and that consent was freely given. The witness and the interpreter may be the same person. The witness may be a family member or friend. The witness may not be a person involved in the design, conduct, or reporting of the research study.
5.2.6 Have the interpreter translate the summary (not the short consent form) to the subject/representative. Begin with a concise and focused presentation of the key information that is most likely to assist the subject/representative to understand the reasons why one might or might not want to participate in the research.

5.2.7 Through the interpreter explain the details in such a way that the subject/representative understand what it would be like to take part in the research study. When necessary provide a different or simpler explanation to make the information understandable.

5.2.8 Have the subject/representative read the short consent form or have the interpreter read the short consent form to the subject/representative.

5.3 If the requirement for written documentation of the consent process has been waived by the IRB:

5.3.1 Obtain the current IRB approved script.

5.3.2 Verify that you are using the most current IRB-approved version of the study specific script and that the script language is understandable to the subject/representative.

5.3.3 When possible provide a copy of the script to the subject/representative.

5.3.4 If the subject/representative cannot speak English, obtain the services of an interpreter fluent in both English and the language understood by the subject/representative. The interpreter may be a member of the research team, a family member, or friend of the subject/representative.

5.3.5 Read the script (or have an interpreter translated the script) with the subject/representative. Begin with a concise and focused presentation of the key information that is most likely to assist the subject/representative to understand the reasons why one might or might not want to participate in the research. Explain the details in such a way that the subject/representative understands what it would be like to take part in the research study.

5.4 Invite and answer the subject/representative’s questions.

5.5 Give the subject/representative time to discuss taking part in the research study with family members, friends and other care providers as appropriate.

5.6 Invite and encourage the subject/representative to take the written information home to consider the information and discuss the decision with family members and others before making a decision.

5.7 Ask the subject/representative questions to determine whether all of the following are true, and if not, either continue the explanation or determine that the subject/representative is incapable of consent:

5.7.1 The subject/representative understands the information provided.

5.7.2 The subject/representative does not feel pressured by time or other factors to make a decision.

5.7.3 The subject/representative understands that there is a voluntary choice to make.

5.7.4 The subject/representative is capable of making and communicating an informed choice.

5.8 If the subject/representative has questions about treatments or compensation for injury, provide factual information and avoid statements that imply that compensation or treatment is never available.

5.9 Once a subject/representative indicates that he or she does not want to take part in the research study, this process stops.

5.10 If the subject/representative agrees to take part in the research study:

5.10.1 If the subject is a child:

5.10.1.1 Whenever possible explain the research to the extent compatible with the child’s understanding.

5.10.1.2 Request the assent (affirmative agreement) of the child unless:
5.10.1.2.1 The capability of the child is so limited that the child cannot reasonably be consulted.

5.10.1.2.2 The IRB determined that assent was not a requirement.

5.10.1.3 Once a child indicates that he or she does not want to take part in the research study, this process stops.

5.10.2 If the subject is an adult unable to consent:

5.10.2.1 Whenever possible explain the research to the extent compatible with the adult’s understanding.

5.10.2.2 Request the assent (affirmative agreement) of the adult unless:

5.10.2.2.1 The capability of the adult is so limited that the adult cannot reasonably be consulted.

5.10.2.2.2 The IRB determined that assent was not a requirement.

5.10.2.3 Once an adult unable to consent indicates that he or she does not want to take part in the research study, this process stops.

5.10.3 Obtain written documentation of the consent process according to “SOP: Written Documentation of Consent (HRP-091).”

6 MATERIALS

6.1 Long form of consent documentation:

6.1.1 Consent form

6.2 Short form of consent documentation:

6.2.1 Short consent form

6.2.2 Summary (same information as the English consent form used for long form of consent documentation)

6.3 Requirement for written documentation of the consent process has been waived by the IRB:

6.3.1 Consent script (same as consent form used for long form of consent documentation except that signature block is optional)


6.5 SOP: Written Documentation of Consent (HRP-091)

7 REFERENCES

7.1 21 CFR §50.20, 50.25

7.2 45 CFR §46.116
SOP: Written Documentation of Consent

1 PURPOSE
1.1 This procedure establishes the process to document the informed consent process in writing.
1.2 The process begins when a subject agrees to take part in a research study.
1.3 The process ends when the consent process is documented in writing, including in an electronic format, to the extent required by this procedure.

2 REVISIONS FROM PREVIOUS VERSION
2.1 None

3 POLICY
3.1 In this procedure “investigator” means a principal investigator or an individual authorized by the principal investigator and approved by the IRB to obtain consent for the specific protocol, such as a co-investigator, research assistant, or coordinator.
3.2 In this procedure “subject/representative” means:
   3.2.1 The subject when the subject is an adult capable of providing consent.
   3.2.2 Legally authorized representative (LAR) when the subject is an adult unable to give consent.
   3.2.3 One or both biologic or adoptive parents when the subject is a child or in the absence of a parent, a person authorized under applicable law to consent on behalf of the child to the child’s general medical care.

4 RESPONSIBILITIES
4.1 The principal investigator is responsible to ensure these procedures are carried out.

5 PROCEDURE
5.1 If the consent process will be documented in writing with the long form of consent documentation:
   5.1.1 Verify that the consent form is in language understandable to the subject/representative.
   5.1.2 Print the name of the following individuals on the consent document:
      5.1.2.1 Subject/Representative
      5.1.2.2 Person obtaining consent
   5.1.3 Have the following individuals personally sign and date the consent document:
      5.1.3.1 Subject/Representative
      5.1.3.2 Person obtaining consent
   5.1.4 If the IRB required written documentation of assent, note on the signature block one of the following:
      5.1.4.1 Assent of the child was obtained.
      5.1.4.2 Assent of the child was not obtained because the capability of the child is so limited that the child cannot reasonably be consulted.
   5.1.5 Have the person obtaining consent personally sign and date the consent document.
   5.1.6 If an impartial witness was part of the consent process:
      5.1.6.1 Print the name of the impartial witness on the consent document.
      5.1.6.2 Have the impartial witness personally sign and date the consent document to attest that the information in the consent document and any other information provided was accurately explained to, and apparently understood by, the subject, and that consent was freely given.
   5.1.7 Provided copies of the signed and dated consent document to the subject/representative. This may be accomplished either by making a photocopy or by having the above individuals sign and date two copies of the consent document.
5.2 If the consent process will be documented in writing with the short form of consent documentation:
   5.2.1 Verify that the short consent form is in language understandable to the subject/representative.
5.2.2 Print the name of the following individuals on the short form consent document and the summary:
5.2.2.1 Subject/Representative
5.2.2.2 Person obtaining consent
5.2.2.3 Impartial witness

5.2.3 Have the following individuals personally sign and date the short form consent document and/or the summary:
5.2.3.1 Subject/Representative sign short form consent document.
5.2.3.2 Person obtaining consent sign short form consent document.
5.2.3.3 Impartial witness sign both short form consent document and summary.

5.2.4 If the IRB required written documentation of assent, note on the signature block on the short consent document one of the following:
5.2.4.1 Assent of the child was obtained.
5.2.4.2 Assent of the child was not obtained because the capability of the child is so limited that the child cannot reasonably be consulted.

5.2.5 Provide a copy of the signed and dated short consent document and a copy of the signed and dated summary to the subject/representative. This may be accomplished either by making photocopies or by having the above individuals sign and date two copies of the short consent document and summary.

5.3 If the requirement for written documentation of the consent process has been waived by the IRB and the IRB determined that the subject/representative had to be offered the opportunity to document his or her consent is writing, offer the subject/representative the option to document his or her consent is writing.
5.3.1 If the subject/representative declines, take no further action.
5.3.2 If the subject/representative accepts, follow the process to document consent in writing with the long or short form of consent documentation

5.4 Place the signed and dated documents in the subject’s binder.

6 MATERIALS
6.1 If the consent process will be documented in writing with the long form of consent documentation:
6.1.1 Consent document

6.2 If the consent process will be documented in writing with the short form of consent documentation:
6.2.1 Short consent document
6.2.2 Summary (same content as the long form of consent documentation)

7 REFERENCES
7.1 21 CFR §50.27
7.2 45 CFR §46.117
1 PURPOSE

1.1 This SOP describes the process for:

1.1.1 Determining whether study-specific risk mitigation plans are needed to address additional research subject safety considerations associated with the COVID-19 pandemic;
1.1.2 Developing study-specific COVID-19 risk mitigation plans;
1.1.3 Communicating study modifications to the IRB; and
1.1.4 Documenting any implemented modifications or deviations from the protocol in the research record.

1.2 The process begins when the investigator considers whether a study-specific risk-mitigation plan is necessary during the COVID-19 pandemic.

1.3 The process ends when the investigator develops the risk mitigation plan or determines that no plan is necessary.

2 REVISIONS FROM PREVIOUS VERSION

2.1 None

3 POLICY

3.1 Effective March 24, 2020 investigators should temporarily place recruitment and ongoing research procedures for Human Research that cannot be done remotely on voluntary hold (with limited exceptions) until further notice due to concerns during the COVID-19 pandemic.

4 RESPONSIBILITIES

4.1 Investigators are responsible to carry out these procedures.

5 PROCEDURE

5.1 Determine whether a COVID-19 risk mitigation plan should be developed for each Human Research project the investigator is leading. A COVID-19 risk mitigation plan should be developed unless one of the following is true:

5.1.1 Research does not involve in-person interaction with research subjects.
5.1.2 Research can be conducted as written while adhering to social distancing requirements and institutional COVID-19 policies and requirements.
5.1.3 Research is externally sponsored, and Sponsor has already developed a COVID-19 risk mitigation plan for the research.
5.1.4 Research has been voluntarily placed on hold for recruitment and all research procedures (with the exception of necessary follow up procedures to be done consistently with social distancing requirements and institutional COVID-19 policies and requirements).

5.2 If an external sponsor has developed a COVID-19 risk mitigation plan for the research, skip to step 5.4.

5.3 For all other research involving in-person interactions with research subjects for which the research cannot otherwise be conducted in accordance with social distancing

---

1 Social distancing recommendations include the following: that people stay at home as much as possible, going out only for critical needs like groceries and medicines, or to exercise and enjoy the outdoors in wide open spaces. Other recommendations include avoiding gatherings of more than 10 people, no handshakes, regular handwashing, and, when encountering someone outside of your immediate household, trying to remain at least 6 feet apart. (Source: NIH Director’s Blog, March 19, 2020)
recommendations, develop a risk mitigation plan in consideration of the potential for direct therapeutic benefit associated with the research.

5.3.1 For research that does not offer potential for direct therapeutic benefit (and is not a Phase I trial with no treatment alternatives):
   5.3.1.1 Develop a plan to place study recruitment and study activities on voluntary hold.
   5.3.1.2 Notify the IRB if study recruitment and research activities cannot be placed on hold for any research requiring in-person interaction but offering no potential for direct therapeutic benefit.

5.3.2 For research that does offer potential for direct therapeutic benefit (or Phase I trial with no treatment alternatives):
   5.3.2.1 Determine whether study should be voluntarily placed on hold to recruitment and/or study conduct, or
   5.3.2.2 Develop more detailed risk mitigation plan, considering the items included in WORKSHEET: Protocol-Specific COVID-19 Risk Mitigation Planning, based on the FDA’s “Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic.”

5.4 Notify the IRB and applicable ancillary review committees (e.g. DSMB, DSMC, etc.) of risk mitigation plan:
   5.4.1 If immediate modification of the research is necessary to eliminate an apparent immediate hazard to a subject, take action and notify the IRB within 5 business days following the standard pathway to submit Reportable New Information.
   5.4.2 For all other study modifications (as described in the UMass Boston COVID-19 Supplement: IRB Guidance on Restarting In-Person Research Activities) made to ensure the ongoing safety of research subjects during the COVID-19 pandemic, submit a study modification to the IRB using "HRP-213 - FORM - Modification."

5.5 Document mitigation plan details in study record in accordance with sponsor and regulatory agency requirements, and in accordance with the information listed in "HRP-350 - WORKSHEET - Research-Specific COVID-19 Risk Mitigation Plan."

6 MATERIALS
   6.1 HRP-213 - FORM - Modification
   6.2 HRP-350 - WORKSHEET - Research-Specific COVID-19 Risk Mitigation Plan

7 REFERENCES
   7.1 FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic